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V. Summary 
Glucocorticoids are regarded as the main therapeutic option for many 
pulmonary diseases, performing outstandingly well in asthmatic patients, however, 
failing to benefit patients suffering from the acute respiratory distress syndrome 
(ARDS), idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease 
(COPD), and impaired lung development associated with bronchopulmonary dysplasia 
(BPD), often seen in pre-term infants. The transforming growth factor (TGF)- 
polypeptide has been implicated as a pathogenic mediator of all of these pulmonary 
pathologies, which prompted us to investigate the crosstalk between glucocorticoid and 
TGF- signaling. The glucocorticoid dexamethasone potentiated the TGF- 
Acvrl1/Smad1/5/8 signaling axis, and inhibited the TGF-β Tgfbr1/Smad2/3 signaling 
axis in NIH/3T3 fibroblast-like mouse cells, in smooth muscle cells, primary lung 
fibroblasts, and endothelial cells. The accessory type III TGF-β receptor (Tgfbr3), which 
is also called betaglycan, was increased by dexamethasone. Betaglycan acted as a 
redirecting “switch” which increased Acvrl1/Smad1 and inhibited Tgfbr1/Smad2/3 
signaling in lung fibroblasts. Dexamethasone activated Acvrl1/Smad1 signaling in 
several constituent pulmonary cell types. Furthermore, this study demonstrated that 
this axis was active in lung fibroblasts, and also inhibited Tgfbr1/Smad2/3 signaling. 
Fibroblast-to-myofibroblast differentiation of primary lung fibroblasts synergistically 
increased during treatment with dexamethasone and TGF-1. This was evident by an 
accumulation of smooth muscle myosin and smooth muscle actin. Previous studies 
have demonstrated that myofibroblast differentiation is exclusively Smad1-dependent. 
Intraperitoneal application of dexamethasone to live C57BL/6J mice resulted in 
increased in vivo pulmonary Tgfbr3 expression and phospho-Smad1 levels. 
Interestingly, this effect was lung-specific. Overall, in this study we demonstrate that 
glucocorticoids impact TGF-β signaling in pulmonary cell types as well as in vivo in 
mice lungs. This may be relevant for normal lung physiology and pulmonary pathology.  
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VI. Zusammenfassung 
Glukokortikoide sind die Therapie der Wahl für viele Erkrankungen der Lunge. 
Während sie erfolgreich in der Therapie des Asthma bronchiale eingesetzt werden, 
scheinen sie kaum einen Nutzen für Patienten zu haben, die an dem akuten 
Atemnotsyndrom (ARDS), der chronisch obstruktiven Lungenerkrankung (COPD), der 
Lungenfibrose sowie an einer Lungenentwicklungsstörung, die eine starke Assoziation 
mit der bronchopulmonalen Dysplasie bei frühgeborenen Kindern aufweist, erkranken. 
Der transforming growth factor (TGF)-β ist ein pathogener Mediator in all diesen 
genannten Lungenerkrankungen, was uns veranlasste, die Interaktion der 
Glukokortikoid – und TGF-β Signalkaskaden zu untersuchen. Das Glukokortikoid 
Dexamethason verstärkte die Acvrl1/Smad1/5/8 TGF-β Signalachse in NIH/3T3 Zellen, 
primären Lungenfibroblasten, glatten Muskel – sowie Endothelzellen, während es die 
Tgfbr1/Smad2/3 Signalachse inhibierte. Dexamethasone erhöhte die Expression des 
akzessorischen Typ III TGF-β Rezeptors Tgfbr3, der auch „betaglycan“ genannt wird. 
Es wurde gezeigt, dass Tgfbr3 als „Schalter“ agierte, der die Tgfbr1/Smad2/3 
Signalachse in Lungenfibroblasten inhibierte sowie die Acvrl1/Smad1/5/8 Signalachse 
potenzierte. Dexamethason stimulierte die Acvrl1/Smad1/5/8 Signalachse in 
Lungenfibroblasten, die antagonistisch zur Tgfbr1/Smad2/3 Signalachse wirkte. 
Weiterhin wirkte Dexamethason synergistisch mit TGF-β auf die Differenzierung von 
primären Lungenfibroblasten zu Myofibroblasten, was durch eine Akkulmulation von 
„smooth muscle actin“ und „smooth muscle myosin“ gezeigt werden konnte. Dieser 
Prozess ist in Fibroblasten ausschließlich Smad1 abhängig. Das Verabreichen von 
Dexamethason an lebende Mäuse zeigte in vivo einen Lungen spezifischen Einfluss 
von Dexamethason auf die Expressionslevel von Tgfbr3 sowie phospho-Smad1 Level. 
Diese Daten weisen auf einen interessanten und bisher unbekannten Einfluss von 
Dexamethason auf die TGF-β Signalachsen in Lungenfibroblasten hin. Wir glauben, 
dass dies für die normale Lungenphysio- und pathophysiologie relevant sein könnte.
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1. Introduction 
 
1.1 Background 
 Glucocorticoids are a class of steroid hormones which bind to the glucocorticoid 
receptor, and thereby impact gene expression in almost every cell type in the body    
[7, 10]. The body produces a natural glucocorticoid called cortisol (or hydrocortisone). 
However, a number of synthetic glucocorticoids have been developed, which are far 
more powerful than cortisol, and which are now widely used as drugs, including 
dexamethasone (dex), methylprednisolone (met), budesonide (bud), and fluticasone 
(flu) [7]. All of these agents have potent anti-inflammatory properties, and have thus 
found application in many acute and chronic lung diseases which have an inflammatory 
component [10]. In some instances, glucocorticoids have demonstrable positive effects, 
and are very successfully used, for example, in asthma and chronic obstructive 
pulmonary disease (COPD) [11, 12]. Surprisingly, however, glucocorticoids are without 
any beneficial effect, or may indeed have a negative impact on many other lung 
diseases which have a pronounced inflammatory component, including idiopathic 
pulmonary fibrosis (IPF), acute respiratory distress syndrome (ARDS), and 
bronchopulmonary dysplasia (BPD) [13-17]. It is currently unclear why glucocorticoids 
do not successfully treat these diseases. The TGF-β signaling system is a signaling 
system that plays an important role in the onset and progression of many lung 
diseases, including IPF, ARDS, and BPD. Increased TGF-β signaling has been 
associated with the increased production of fibrotic components in IPF and BPD, and 
also has been associated with increased pulmonary edema in ARDS [18-22]. Studying 
the interaction of these two major signaling pathways may provide new insights into 
why glucocorticoids, despite their pronounced anti-inflammatory activity, have not 
helped patients who suffer from these devastating pulmonary diseases.  
 
1.2 Transforming growth factor-β 
 The TGF-β superfamily is a family of growth factors and consists of 33 ligands 
controlling a wide range of cellular processes during embryogenesis and later on in 
adult homeostasis [23]. These physiological processes include regulation of cell 
proliferation, migration, differentiation, apoptosis, extracellular matrix (ECM) production 
and maintenance, as well as of the immune system [24-30]. The three TGF-β isoforms 
and the ten isoforms of the bone morphogenetic protein (BMP) family are well-known 
ligands of this family [23]. 
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1.2.1 TGF-β ligands 
 Three TGF-β isoforms have been described, TGF-β1, TGF-β2, and TGF-β3. 
Each isoform is encoded on a different gene [31-33]. Then TGF-β1 is secreted from 
cells in a latent dimeric complex which contains an amino-terminal pro-domain, also 
called TGF-β latency-associated protein (LAP), and a carboxy-terminal domain 
containing the mature TGF-β [2, 34, 35]. Then, two pro-polypeptide chains form a 
disulfide-bonded homodimer [2, 35, 36]. Next, TGF-β is cleaved from the propeptide by 
furin convertase [2, 37]. However, after cleavage the TGF-β dimer and the LAP 
propeptide remain associated by non-covalent interactions and form the so-called small 
latent TGF-β complex [2]. This complex is then non-covalently linked with a latent  
TGF-β binding protein (LTBP) and forms the large latent TGF-β complex [2]. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.1 Organization of the functional region of the latent transforming growth factor-β-binding protein-1S. 
Extracellular matrix is abbreviated as ECM. N represents the N-terminal end of the protein. C represents the C-terminal 
end of the protein. This image was taken from Unsöld et al. (2001) [1]. 
 
1.2.2 Activation of TGF-β 
 The release of active TGF-β from matrix-associated latent complexes requires 
two steps [2] (Fig. 1.2). First the complex has to be released from the ECM by 
proteolysis, and secondly inactive TGF-β has to be activated, which can take place via 
various mechanisms [2]. Multiple proteinases including plasmin are able to release 
TGF-β from the ECM by cleavage of the protease-sensitive hinge region of the LTBP 
[2, 38]. A proteolytic step is then needed to release TGF-β from the LAP [2]. This can 
be achieved by several mechanisms [2]. 
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Fig. 1.2 From synthesis to activation. After synthesis inactive TGF-β is secreted from the cell and associates with 
extracellular matrix components. After release inactive TGF-β can be transformed into the active form by several 
mechanisms. This image was taken from Koli et al. (2001) [2]. 
 
 These mechanisms can be physiochemical or enzymatic reactions which 
include an acidic cellular microenvironment, reactive oxygen species, matrix 
metalloproteinase (MMP)-2, MMP-9, and integrin alpha v beta 6 (αvβ6) [2, 39-42]. 
Interestingly, TGF-β activation can also be induced by certain drugs including retinoids 
and glucocorticoids [2, 43, 44]. 
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1.2.3 TGF-β receptors 
Members of the TGF-β family are able to signal through a family of transmembrane 
protein serine/threonine kinases consisting of type I and type II receptors [47, 48]    
(Fig. 1.3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.3. Schematic representation of transforming growth factor-β receptors. This representation also 
demonstrates the relationship of TGF-β ligands with ligand-binding traps, accessory receptors, and type I and type II 
receptors in vertebrates. Following abbreviations are used in this image, α2-M (α2-macroglobulin), GDF1               
(growth differentiation factor-1), Vg1 (vegetalising factor-1), GFD5 (growth and differentiation factor-5), AMH               
(Anti-Müllerian hormone), MIS (Müllerian-inhibitory substance), TβR-I and II (transforming growth factor-β receptor I  
and II), ActR-IIb (activin A receptor type IIb),  ALK (activin receptor-like kinase), BMPR-II (bone morphogenetic protein 
receptor type II), AMHR-II (Anti-Müllerian hormone receptor II). This image was taken from Shi et al. (2003) [45].  
 
Each receptor type is made up of approximately 500 amino acids organized into 
an extracellular ligand-binding domain, a transmembrane domain, and an intracellular 
signaling serine/threonine kinase domain [45, 49-52]. In the human genome this 
receptor family consists of seven type I and five type II receptors [45, 46].  
 
1.2.4 Signal transduction mechanism and Smad proteins 
 Both type I Tgfbr1 and type II Tgfbr2 receptors are crucial for TGF-β-mediated 
signal transduction [48, 53, 54] (Fig. 1.4). Activated TGF-β binds to the Tgfbr2 with high 
affinity [47, 55]. Upon activation the Tgfbr2 activates the Tgfbr1 by phosphorylation and 
both receptors form a heteromeric complex [47, 53, 56-59]. Transforming             
growth  factor-β preferably signals through the type I activin receptor-like kinase 5 
receptor (ALK5, Tgfbr1 ) [60]. However, it has also been demonstrated that TGF-β can 
signal through the type I activin receptor-like kinase 1 receptor (ALK1, Acvrl1) [61]. 
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Fig. 1.4 Schematic representation of the downstream transforming growth factor-β signaling system. Following 
abbreviations are used in this image, Tgfbr1, 2, and 3 (transforming growth factor-β receptor 1, 2, and 3), Acvrl1   
(activin A receptor type II-like 1), ALK (activin receptor-like kinase), ActR-II (activin A receptor type IIb), BMPR-II     
(bone morphogenetic protein receptor type II), ERK1/2 (extracellular regulatory kinase 1/2), MAPK (mitogen-activated 
protein kinase), JNK (c-Jun N-terminal-kinase), PI3K (phosphoinositide 3-kinase), CBP/P300 (CREB-binding 
protein/adenovirus early region 1A-binding protein), SBE (Smad-binding element), Sno (Sno oncogene). This image 
was taken from Bobik (2006) [3] and modified. 
 
The Smad proteins carry TGF-β superfamily member-mediated signals from the 
cell surface to the nucleus [4]. There are eight known proteins that belong to this   
family [4] (Table 1.1). They can be classified into three groups: firstly,               
receptor-regulated Smads (R-Smads; Smad1, Smad2, Smad3, Smad5 and Smad8), 
secondly, the common-mediator Smad (co-Smad; Smad4), and thirdly, the inhibitory 
Smads (I-Smads; Smad6 and Smad7) [4].  
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Table 1.1 Conservation of Smad proteins in vertebrates, Drosophila, and C. elegans 
 
Species Receptor-regulated Common Inhibitory 
Vertebrates Smad1 
Smad5        
Smad8 
Smad2 
Smad3 
Smad4 Smad6 
Smad7 
Drosophila Mad Medea Dad 
C. elegans Sma2 
Sma3 
Sma4 Daf-3 
 
Following abbreviations were used in this table, Mad (Drosophila mothers against dpp), Dad (diaphanous autoregulatory 
domain), Daf-3 (gene that encodes an inhibitory Smad). This image was taken from Attisano et al. (1998) [4] and 
modified. 
 
Smad2 and Smad3 induce TGF-β/Activin responses, whereas Smad1, Smad5, 
and Smad8 induce BMP responses [4, 62-66]. Smad activation relies on 
phosphorylation [4]. Smad2 and Smad3 are specifically phosphorylated by the 
activated Tgfbr1 [4, 67, 68]. After activation, phospho-Smad2 and phospho-Smad3 
form a heteromeric complex with Smad4 in order to translocate to the nucleus            
[4, 69, 70]. 
Phospho-Smad1, phospho-Smad8, and possibly phospho-Smad5 form a 
complex with Smad4 after activation by BMP [4, 63, 70]. The inhibitory Smad6 and 
Smad7 proteins act as negative regulators of BMP and TGF-β signaling, due to the 
ability to prevent phosphorylation and association of R-Smads [4, 71-73]. Furthermore, 
Smad7 specifically antagonizes TGF-β signaling, whereas Smad6 antagonizes BMP 
signaling [4, 71-73].    
 
1.2.5 Gene regulation 
Activated R-Smad/co-Smad complexes translocate to the nucleus influencing a 
wide spectrum of transcriptional regulation [4]. These complexes bind to the so-called 
Smad-binding element (SBE), which are formed by certain nucleotide repeat 
sequences and are situated in promoter or suppressor regions of certain genes        
[45, 74, 75]. The minimal SBE consists of four base pairs, 5′-AGAC-3′ [45, 76]. In most 
natural DNA sequences an extra C base pair is additionally situated at the 5′ end [45].         
TGF-β-mediated signaling influences multiple cellular functions by transcriptional 
regulation of target genes [23-30].  
BMP 
TGF-β 
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Well-known target genes of downstream TGF-β induction are the profibrotic 
factors SERPINE1 (encodes plasminogen activator inhibitor-1) and CCN2 (encodes 
connective tissue growth factor), as well as COL1A1 (encodes pro-collagen 1), 
COL3A1 (encodes pro-collagen 3), ACTA2 (encodes α-smooth muscle actin), and 
SMAD7 [25, 27, 74, 76, 77]. Known target genes of downstream BMP signaling include 
ID1 (encodes inhibitor of differentiation-1) and SMAD6 [78-80]. 
 
1.2.6 TGF-β co-receptors 
In addition to type I and type II receptors a third family of type III receptors 
exists [47]. This family consists of the two related proteins, namely Tgfbr3 or 
betaglycan; and endoglin [47, 81, 82]. It has been demonstrated that these two 
receptors are capable of binding TGF-β ligands and forming complexes with type I and 
type II receptors and are, therefore, able to modulate TGF-β signaling [47, 83-85].  
 
1.2.7 Betaglycan: an accessory TGF-β receptor 
 Betaglycan is a membrane-anchored proteoglycan which consists of 853 amino 
acids and belongs to the family of type III receptors [47, 81, 83, 86] (Fig. 1.5). 
Compared with type I and type II receptors, betaglycan does not have an intrinsic 
cytoplasmic signaling function [47, 81, 87]. The extracellular domain binds TGF-β 
isoforms with high affinity and also facilitates TGF-β ligand-binding to the type II 
receptor [47, 83, 87-89]. It has also been demonstrated that betaglycan binds BMP 
extracellularly, enhancing ligand-binding to BMP type I receptors, and is, therefore, 
also capable of modulating downstream BMP signaling [80, 90].  
 
  
 
 
 
 
 
 
 
 
 
 
Fig. 1.5 Schematic structure of betaglycan. Following abbreviations were used in this image, MMP                     
(matrix metalloproteinase), PDZ (post synaptic density protein, Drosophila disc large tumor suppressor, zonula 
occludens protein-1). This image was taken from Bilandzic et al. (2011) [5]. 
 
Introduction                                                                                                                  8 
 As betaglycan is able to directly interact with type I and type II receptors, it is a 
major determinant of cellular responsiveness to TGF-β superfamily members [5]. 
Depending on cell type and context-dependent mechanisms, betaglycan can either 
inhibit or enhance signaling properties of certain TGF-β superfamily members [5]. 
Stenvers and colleagues revealed that betaglycan-deficient mice developed lethal 
proliferative effects in the heart and apoptosis in the liver, which suggests a crucial role 
of betaglycan for normal organ development [91]. 
 
1.2.8 Tgfbr1 versus Acvrl1 signaling 
 TGF-β is capable of signaling via the Tgfbr1/Smad2/Smad3 as well as via the 
Acvrl1/Smad1/Smad5/Smad8 axis [92]. This may at least be partly dependent on   
TGF-β receptor expression levels [93].  
In most cell types TGF-β favors the Tgfbr1/Smad2/Smad3 axis [92]. This 
pathway is known to drive profibrotic and fibrotic factors such as SERPINE1, CCN2, 
ACTA2, COL1A1, or COL3A3 [25, 27, 76, 77]. Dysregulation of the 
Tgfr1/Smad2/Smad3 axis has been implicated in many lung pathologies in which 
fibrosis and inflammation are the underlying causes in the pathogenesis of disease 
development and progression [18-22, 94-97]. 
However, in endothelial cells it was documented that the other type I receptor, 
Acvrl1, was predominantly expressed, thereby, favoring TGF-β signaling via the 
Acvrl1/Smad1/5/8 axis in this cell type [92, 98]. Further investigation into this 
phenomenon revealed that both signaling pathways were active in this cell type and 
that both revealed opposite effects in terms of cellular responses to TGF-β stimulation 
[92]. While stimulation of the Tgfbr1/Smad2/Smad3 axis increased serpine1 expression 
levels and inhibited endothelial cell proliferation and migration, the Acvrl1/Smad1/5/8 
axis promoted proliferation and migration [92]. Mutations in Acvrl1 and endoglin, a 
TGF-β accessory receptor, have been linked to the human vascular disorder, 
hereditary hemorrhagic telangiectasia (HHT) [92, 99]. Interestingly, TGF-β-induced 
Smad1/Smad5 signaling has also recently been reported in epithelial cells,     
epithelium-derived tumor cells, and fibroblasts [100-102].  
 Furthermore, it has been found that fibroblasts from patients suffering from 
systemic sclerosis revealed increased SMAD1 phosphorylation and that this correlated 
with increased amounts of the profibrotic CTGF protein [103]. A further study 
demonstrated that id1, a target gene of the Acvrl1/Smad1/5/8 axis, and Smad1 
phosphorylation levels were co-induced during a model of fibrogenesis in rats, 
concluding that these components might be involved in hepatic fibrosis [104]. 
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1.2.9 TGF-β signaling in lung development 
Transforming growth factor-β is widely implicated in early and postnatal lung 
development [105]. In general, lung development can be divided into six stages: the 
embryonic, pseudoglandular, canalicular, saccular, and alveolar stages, as well as the 
stage of vascular maturation [106]. During development the lung strives to maximize 
the surface area for gas exchange while minimizing the thickness of the 
alveolocapillary barrier [105-107].  
Experimentally, it was demonstrated that between postnatal days 7 and 14, 
conditional TGF-β1 overexpression in fetal monkey lungs severely impaired postnatal 
lung development [108]. This resulted in disrupted alveolarization, a key feature 
observed in BPD, suggesting that increased TGF-β signaling during this period of lung 
development inhibits alveolarization [105, 108]. Paradoxically, the inhibition of TGF-β 
signaling achieved in Smad3-deficient mice between postnatal days 14 and 28 resulted 
in airspace enlargement, indicating that during this period of lung maturation TGF-β 
signaling has a positive regulatory effect on alveolarization [21, 105, 109]. This leads to 
the so-called “Goldilocks” hypothesis, meaning that at certain points in time during lung 
maturation TGF-β signaling has to be “just right” for normal pre- and postnatal lung 
development [110]. 
 During lung maturation in mice and humans, TGF-β receptor expression levels 
vary [111]. Alejandre-Alcázar et al. revealed that tgfbr1 expression levels steadily 
decreased and acvrl1 expression levels steadily increased in developing mouse lungs 
[111]. The TGF-β receptor 1 is known to control ECM deposition and remodeling while 
Acvrl1 is believed to play a key role in the endothelium during the phase of vessel 
maturation [47, 111, 112]. However, Alejandre-Alcázar’s study also demonstrated that 
Acvrl1 was expressed in vascular smooth muscle as well as in airway epithelium where 
the function remains unclear [111]. The same study also revealed that expression 
levels of the type III receptor betaglycan increased during the late phase of postnatal 
lung development [111].  
 
1.2.10 TGF-β signaling in lung disease  
It is thought that dysregulation of the TGF-β signaling pathway contributes to 
disease development and progression in fibrotic and inflammatory lung diseases such 
as BPD, IPF, ARDS, asthma, and COPD [19, 22, 113-120]. In the following chapter, 
these lung pathologies and the role of TGF-β in disease pathogenesis will be briefly 
discussed. 
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Bronchopulmonary dysplasia is characterized by diffuse pulmonary 
inflammation with alveolar and vascular simplification and an arrest of lung 
development, resulting in a reduced surface area for gas exchange and chronic 
pulmonary disease [121]. It affects prematurely born babies [94]. 
 The multifactorial pathogenesis of BPD is complex and includes infection, 
inflammation, ventilator-induced lung injury, oxidant stress, abnormal growth factor 
signaling, and genetic factors [94]. Increased active and total TGF-β1 levels were found 
in bronchoalveolar lavage fluid (BALF) obtained from infants suffering from chronic lung 
disease (CLD) [113]. Experiments in animals have revealed that inflammation 
increased total TGF-β1 levels and that excessive TGF-β signaling in the developing 
lung led to interstitial fibrosis and inhibition of alveolar septation, both key features of 
BPD [19, 122].  
 Further experiments which gave insights into the involvement of TGF-β 
signaling in BPD pathogenesis have also demonstrated that high tidal ventilation and 
hyperoxia resulted in increased TGF-β signaling, and also in increased myofibroblast 
differentiation, and that this again was associated with arrested alveolar development 
[123, 124]. 
 
 Idiopathic pulmonary fibrosis is defined as a specific form of chronic, 
progressive fibrosing interstitial pneumonia, is characterized by progressive worsening 
of dyspnea and deterioration of lung function, and is associated with a poor prognosis 
[13]. Key histopathological features include alveolar destruction, excess collagen 
deposition and remodeling, which is thought to be the result of excessive interstitial 
inflammation triggered by an initial inflammatory lesion within an alveolus [114, 125].  
 As IPF patients respond poorly to anti-inflammatory therapy, especially 
corticosteroids, inflammation does not seem to feature prominently in the pathogenesis 
of disease progression [13, 14, 18, 20, 126]. Transforming growth factor-β is a major 
contributor to fibrogenesis and, therefore, believed to play a key role in the progression 
of IPF [18]. In several studies, Khalil and co-workers revealed that IPF patients 
produced significantly more TGF-β and that this resulted in higher pulmonary TGF-β1 
levels [114, 115, 127]. Experimental studies demonstrated that Smad3-deficient mouse 
lungs developed only little evidence of fibrosis and no upregulation of             
fibrogenesis-associated genes, suggesting a key role for Smad3 as an intracellular 
mediator of TGF-β signaling in the pathogenesis of progression in IPF [18, 21]. 
 
 Acute respiratory distress syndrome, according to the new “Berlin 
Definition”, is clinically characterized by hypoxemia and bilateral radiographic opacities, 
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associated with increased venous admixture, increased physiological dead space, and 
decreased lung compliance [128]. This syndrome is defined by diffuse bilateral 
inflammation leading to increased pulmonary vascular permeability, increased lung 
weight, and loss of aerated lung tissue [128]. 
 Acute respiratory distress syndrome can be the result of multiple etiologies 
causing acute lung injury and tissue inflammation such as sepsis, pancreatitis, 
hemorrhagic shock, or toxic inhalation [22]. As far as the pathogenesis is concerned, 
TGF-β is seen as a key mediator of ARDS [22, 116]. It plays a major role in the 
development of fibrosis during the late phase of ARDS [22, 129]. However, BALF 
collected from ARDS patients within 48 hours after intubation already contained 
elevated levels of active TGF-β1 compared to controls [116, 130]. 
 Destruction of epithelial barrier integrity is central to the early stage of ARDS 
causing alveolar edema [22]. It has been demonstrated that TGF-β1 disrupts epithelial 
integrity, thus allowing fluid to flood the alveolus, which in turn leads to hypoxemia [22]. 
However, not only epithelial integrity but also fibroproliferation and increased collagen 
turnover occur in the early phase of ARDS and impact disease outcome [130-132]. 
Plasmids containing the procollagen I promoter which were transfected into normal 
human fibroblasts were significantly induced by BALF obtained from ARDS patients 
compared to controls [130]. This effect was attenuated with a specific TGF-β1 antibody 
[130]. This study suggests that TGF-β1-induced fibrotic changes already occur in early 
stages of this syndrome. 
 
 Asthma is a chronic disease characterized by airway inflammation and 
remodeling accompanied by airway hyperresponsiveness, and reduced lung function 
[96]. This disease is one of the most common chronic diseases affecting nearly 300 
million people worldwide [96]. Together with many other cytokines, TGF-β1 plays a 
central role in airway remodeling which includes microvascular changes, airway 
smooth muscle remodeling, and subepithelial fibrosis, key histopathological features of 
asthmatic patients [96, 97].   
Other studies have demonstrated that eosinophilic cells isolated from BALF 
obtained from asthmatic patients demonstrated increased TGF-β1 mRNA levels, which 
suggests that eosinophils may be important for the pathogenesis of inflammation and 
also capable of influencing specific structural changes such as subepithelial fibrosis 
[118]. Furthermore, alveolar macrophages isolated from BALF from asthmatic patients 
revealed an increased release of TGF-β1 when challenged with allergens compared to 
controls [133]. Bottoms and co-workers revealed that a specific TGF-β1 antibody 
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inhibited ovalbumin-induced subepithelial collagen deposition, airway and fibroblast 
decorin deposition, as well as monocyte and macrophage recruitment [97]. 
 
 Chronic obstructive pulmonary disease is characterized by chronic airway 
inflammation accompanied by irreversible expiratory airflow limitation, which is caused 
by small airway disease (SAD) and emphysema [96]. Today COPD is one of the 
leading causes of death in the developed world and is associated with a high individual 
and socioeconomic burden [134]. Risk factors for COPD include tobacco smoke, 
genetic predisposition, occupational and environmental exposure, as well as asthma 
[96, 135]. 
 Chronic inflammation and also dysregulation of TGF-β signaling are important 
regulators in the pathogenesis of this disease [96]. Small airway disease causes 
expiratory airflow limitation and is characterized by increased airway wall thickness as 
a result of tissue remodeling and peribronchiolar fibrosis [134, 136]. Transforming 
growth factor-β is known to drive fibrogenic processes [134, 137]. It has been 
demonstrated that TGF-β1 mRNA expression levels were significantly upregulated in 
small airway epithelium of tobacco smokers and COPD patients [119, 138]. 
Furthermore, mRNA levels of the inhibitory Smad6 and Smad7 in bronchial biopsies 
were significantly decreased in COPD patients, suggesting a disturbed intracellular 
negative feedback mechanism of TGF-β signaling [120]. It has been revealed that 
cultured human fetal lung fibroblasts demonstrated increased production of TGF-β1 
mRNA when challenged with cigarette smoke [139]. Further investigation into the 
function of pulmonary fibroblasts in COPD in vivo revealed that these cells produced 
increased amounts of TGF-β1 and also revealed increased responses to TGF-β     
[140, 141]. 
 In the case of emphysema, decreased TGF-β signaling seems to contribute to 
the development of airspace enlargement [134, 142]. Smad3 knock-out mice 
spontaneously develop enlarged airspaces and are protected from fibrosis [21, 109]. 
 
1.2.11 Fibroblast-to-myofibroblast differentiation 
 Tissue injury activates a repair response in which fibroblasts play an essential 
role [143]. Upon injury fibroblasts are activated or differentiate to myofibroblasts in 
order to participate in wound repair [143]. In this activated or transdifferentiated state 
they represent a key source of ECM components, inflammatory and fibrogenic 
cytokines, and participate in wound contraction [143]. It has been demonstrated that 
TGF-β1 is a strong activator of fibroblast-to-myofibroblast differentiation [144, 145]. As 
wound repair continues, myofibroblasts should gradually disappear [143]. However, 
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persisting myofibroblasts are associated with the development and progression of 
fibrosis seen in IPF, BPD, and ARDS [143]. Alpha-smooth muscle actin (ACTA2) and 
smooth muscle myosin heavy chain (MYH11) represent two markers of myofibroblast 
differentiation [144-146]. It has been demonstrated that α-smooth muscle actin 
expression is regulated by the Acvrl1/Smad1 pathway, which suggests that this 
pathway is a regulator of myofibroblast differentiation [147-151]. 
 
1.3 Glucocorticoids 
 Glucocorticoids are endogenously-produced steroid hormones [8]. 
Physiologically, the most important glucocorticoid is cortisol [8]. Depending on the rate 
of secretion and tissue concentration, cortisol influences a broad spectrum of 
physiological processes in the body [8]. 
 
1.3.1 Glucocorticoid effects in the human body 
At physiological concentrations cortisol causes catabolic effects which include 
degradation of proteins, stimulation of gluconeogensis and the production of glycogen 
in the liver, and also enhances lipolytic effects of catecholamines [8]. Furthermore, 
cortisol increases sodium retention as well as potassium and calcium secretion in the 
kidney [8]. During periods of physical stress cortisol secretion is increased, and at 
higher concentrations cortisol has an anti-proliferative effect on fibroblasts and blocks 
the synthesis of collagen [8]. Cortisol also has pronounced anti-inflammatory 
properties, blocking unspecific and specific defense mechanisms and preventing        
T-lymphocyte proliferation [8]. Increased cortisol concentrations can also cause 
increased excitability of the brain and euphoric or depressive effects [8]. 
 
1.3.2 Glucocorticoid cell signaling 
 Glucocorticoids are lipophilic molecules and, therefore, bind to an    
intracellularly-located glucocorticoid receptor (GR) [8]. 
 
1.3.3 The intracellular glucocorticoid receptor 
 Glucocorticoid receptors are located in the cytoplasm of the cell and are 
ubiquitously expressed [6]. Heat-shock proteins are responsible for the correct folding 
of the GR [6]. The whole receptor is made up of three domains [6] (Fig. 1.6). 
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Fig. 1.6 Representation of the intracytoplasmic-located glucocorticoid receptor. This image was taken from 
Mutschler et al. (2001) [6] and modified.  
 
1.3.4 Signal transduction 
 Cortisol is able to pass the lipophilic cell membrane and can then bind the 
ligand-binding domain at the C-terminus of the GR to form the ligand-receptor complex 
[6] (Fig. 1.7). Upon ligand binding, heat-shock proteins dissociate from the receptor [6]. 
After activation, the ligand-receptor complex passes to the nucleus, where the 
activated ligand-receptor complex then has two possibilities. Firstly, the DNA-binding 
domain can bind to specific glucocorticoid responsive elements (GRE) located on the 
DNA [6]. The transactivating domain is then able to activate or deactivate gene 
transcription [6]. Secondly, the ligand-receptor complex can bind directly to other 
transcription factors in the nucleus [6]. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.7 Schematic representation of downstream glucocorticoid signaling. After entering the nucleus the activated 
glucocorticoid receptor (GR) is able to influence gene expression in several ways [7]. Glucocorticoid receptors bind to 
glucocorticoid responsive elements (GREs) in promoter or suppressor regions of steroid-sensitive genes [7]. They may 
promote expression of anti-inflammatory genes such as annexin 1, SLPI (secretory leukoprotease inhibitor), MKP 
(mitogen-activated protein kinase phosphatase)-1, IκB-α (nuclear factor of kappa light polypeptide gene enhancer in    
B-cells inhibitor, alpha) or GILZ (glucocorticoid-induced leucine zipper protein) [7]. On the other hand, they may repress 
expression of genes commonly related to side-effects of corticosteroids such as POMC (pro-opiomelanocorticotropin), 
CRF (corticotropin releasing factor), osteocalcin, and keratin [7]. Furthermore, they are able to interact with other 
transcription factors such as CBP (cAMP-response-element-binding-protein), which is activated by the pro-inflammatory 
transcription factor NF-κB [7]. This image was taken from Barnes (2006) [7].  
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1.3.5 Regulation of glucocorticoid concentrations in the body 
Cortisol concentrations in the body are strictly regulated by the hypothalamus 
and the pituitary gland [8] (Fig. 1.8). When cortisol levels in the body drop, 
corticotropin-releasing hormone (CRH) is secreted from the hypothalamus, which then 
stimulates the secretion of adrenocorticotropic hormone (ACTH) in the pituitary gland 
[8]. Adrenocorticotropic hormone then stimulates cortisol production in the adrenal 
cortex [8]. 
Cortisol production and secretion is regulated by a negative feedback loop 
mechanism in which cortisol inhibits the secretion of CRH from the hypothalamus and 
the secretion of ACTH from the pituitary gland [8]. Cortisol levels in the body vary 
greatly during the day [8]. Between 9 a.m. and midday plasma levels reach the highest 
concentration, while the lowest levels are reached at around midnight [8]. Stressful 
situations of a physical or psychological nature greatly stimulate cortisol production and 
secretion from the adrenal cortex [8]. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.8 Schematic representation of glucocorticoid regulation in the body. This image was taken from Mutschler 
et al. (2001) [8] and modified. 
 
1.3.6 Cortisol synthesis 
 Anatomically, the adrenal gland is situated above the kidney. Histologically, the 
gland consists of the cortex and the medulla [152]. Furthermore, the adrenal cortex is 
divided into three different zones: the zona glomerulosa, zona fasciculate, and the zona 
reticularis [152]. Cortisol is produced in cells that are situated in the zona fasciculate 
and zona reticularis [152]. Cholesterol forms the basis of cortisol                      
synthesis [9] (Fig. 1.9). 
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Fig. 1.9 Schematic representation of the cortisol synthesis pathway. This image was taken from Freel et al.   
(2004) [9]. 17α-OH (17-alpha hydroxylase); 3β-HSD (3-beta hydroxysteroid dehydrogenase); CYP (cytochrome p). 
 
1.3.7 Cortisol derivatives 
 On the basis of the pronounced anti-inflammatory, anti-allergic, and 
immunosuppressive properties, glucocorticoids have found widespread clinical 
application [8]. Over the years a wide range of cortisol derivatives has been developed 
that differ structurally from one another [8].  
 
1.3.8 General clinical use of glucocorticoids 
  On the basis of the previously described physiological and pharmacological 
properties (see chapter 1.2.1), glucocorticoid derivatives are frequently used in patients 
suffering from adrenal insufficiency or from diseases in which inflammation is a key 
component for disease development, progression, or worsening [8]. The                  
anti-inflammatory and immunosuppressive effects of glucocorticoids benefit patients 
suffering from autoimmune diseases such as rheumatoid arthritis or organ transplant 
patients by suppressing immunologic rejection [8]. Furthermore, corticosteroids find 
clinical application in patients suffering from certain allergic conditions, such as allergic 
rhinitis and conjunctivitis, certain dermatologic diseases such as urticaria, or oncologic 
diseases such as acute lymphoblastic leukemia (ALL) [8]. 
 
1.3.9 Adverse effects of glucocorticoids 
 Adverse impacts of glucocorticoids are determined by their physiological effects 
in the body [8]. Side effects increase with duration of treatment as well as dosage [8]. 
These effects include an increased risk of infection, delayed wound healing, muscle 
and skin atrophy, growth inhibition in children, and an increased risk of developing 
osteoporosis and diabetes. Further adverse effects include an increase in retention of 
sodium and water, an increased excretion of potassium, impacted central nervous 
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functions, the risk of developing glaucoma, Cushing’s syndrome, and an increased risk 
of thrombosis [8]. 
 
1.3.10 Glucocorticoids in TGF-β-related lung pathologies and lung development 
 The following section will give a short summary of glucocorticoid effects on 
TGF-β-related lung pathologies and lung development. 
 
 Lung development and BPD: Animal studies have demonstrated that 
glucocorticoids impact the speed of lung maturation and the critical stage of 
alveolarization [153-155]. Preterm Rhesus monkeys that were antenatally treated with 
betamethasone demonstrated accelerated lung maturation but an overall decreased 
amount of alveoli compared to controls [153, 154]. Similar results were found in a 
further study investigating the effect of dex on postnatal lung development in newborn 
rats, which revealed that steroid therapy resulted in an “emphysematous” lung with 
larger and fewer airspaces [153, 155]. 
 One fundamental problem of respiratory adaptation in premature newborns 
(born before 37 weeks of gestation) is the inability to synthesize sufficient amounts of 
surfactant, which prevents the alveoli from collapsing, and, therefore, ensures blood 
oxygenation [156]. Antenatal administration of glucocorticoids increases mRNA levels 
of surfactant protein A and B in rat and human lungs [153, 157, 158]. However, another 
study found that when infants at risk of developing CLD were treated with 
corticosteroids at 14 days of age, they did not demonstrate any improvement in 
surfactant function, suggesting that the time point of drug administration is critical   
[153, 159]. 
 The question of whether or not to treat newborns at risk of, or suffering from, 
BPD remains a difficult one to answer [17]. One small clinical study has demonstrated 
that short-term treatment with dex improved pulmonary function, suppressed 
pulmonary inflammation, and decreased respiratory support in premature infants 
suffering from BPD [160]. A review from 2010 states that using high daily doses of dex 
(approximately 0.5 mg/kg/d) reduces the incidence of BPD, but is also associated with 
numerous short- and long-term adverse outcomes including neurodevelopmental 
impairment [17]. Furthermore, there is insufficient evidence that low-dose               
(<0.2 mg/kg/d) dex therapy is beneficial [17]. The same applies to the use of both low 
and high dose hydrocortisone therapy [17]. Therefore, open-label glucocorticoid 
therapy cannot be recommended for infants suffering from BPD [17]. 
 In one experiment, betamethasone even worsened chorioamnionitis-related 
lung development in rabbits, suggesting that glucocorticoid treatment might represent 
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an additional risk factor for lung development in the case of preterm infection, which is 
also a risk factor for developing BPD [161, 162]. 
 
 In IPF to date, no randomized controlled studies have been conducted with 
corticosteroid monotherapy [13, 163, 164]. Retrospective uncontrolled studies have 
reported no survival benefit, although a minority of patients demonstrated improved 
pulmonary function [13, 14, 165]. However, long-term corticosteroid therapy resulted in 
substantial morbidity [13, 165]. Based on these clinical facts, the current 
recommendation states that IPF patients should not receive corticosteroid 
monotherapy [13]. 
 As IPF patients respond poorly to anti-inflammatory therapy, it has been 
suggested that inflammation may not play a key role in the pathogenesis of disease 
progression [14, 18, 20, 126]. Another possible explanation why glucocorticoids do not 
improve the status of fibrosis patients is that they are unable to inhibit interleukin     
(IL)-13-mediated differentiation of fibroblasts into myofibroblasts [166, 167]. 
 
 Acute respiratory distress syndrome today remains a devastating syndrome 
and despite therapeutic advances, mortality rates still vary between 25-40% [15]. 
Currently, no drug therapy can be recommended for patients suffering from this 
devastating disease [15]. A clinical study exploring the effects of systemically-applied 
met to ARDS patients published in The New England Journal of Medicine in 2006 
came to the conclusion that met should not be routinely used in patients suffering from 
persistent ARDS [16]. Furthermore, the study concluded that systemic met therapy 
administered more than two weeks after onset of ARDS might even increase the risk of 
mortality [16]. Fluid management, low tidal ventilation in sedation, the abdominal 
position, and extracorporeal membrane oxygenation (ECMO) remain the main 
strategies to improve outcome for ARDS patients [15]. 
 
 Asthma: Currently, a wide range of drugs is available to asthmatic patients, 
whereas therapeutic options depend on age, progression, and severity of the disease 
[11]. Drug therapy consists of two components: quick relief medication including    
short-acting β2-agonists and long-term control medication including inhaled 
corticosteroids (ICS) [11]. These types of drugs include bud and flu and are the most 
effective long-term control medication in asthmatic children and adults [11]. Inhaled 
corticosteroids reduce airway hyperresponsiveness, inhibit inflammatory cell migration 
and activation, block late-phase reaction to allergens, and reduce the risk of 
Introduction                                                                                                                  19 
exacerbation [11]. However, these drugs have failed to alter the progression or 
underlying severity of the disease in children [11]. 
 
 Chronic obstructive pulmonary disease is, by its very nature, a chronic 
progressive disease that cannot be treated curatively [12]. The goal of COPD treatment 
is thus the reduction of long-term function decline, preventing and treating 
exacerbations, reducing the number of hospitalizations and mortalities, relieving 
disabling dyspnea, and improving exercise tolerance as well as the health-related 
quality of life [12]. As in the treatment of asthma, drug treatment depends on disease 
severity and stability [12]. Inhaled corticosteroids are regularly used in combination with 
inhaled β2-agonists or inhaled anticholinergics but can also be employed in 
monotherapy [12]. It has been proven that flu reduced exacerbations in COPD patients 
[12, 168]. Furthermore, it has been demonstrated that there were significantly fewer 
cases of dyspnea in patients receiving ICS therapy compared to placebo [12, 169]. 
However, this same clinical study also concluded that patients receiving ICS therapy 
did not benefit in terms of frequency of hospitalizations [12, 169]. 
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2. Aim of the study 
 Dysregulation of TGF-β signaling has been implicated in many devastating lung 
diseases in which fibrosis and inflammation are central features of pathogenesis      
[19, 22, 113-120]. Glucocorticoids have proven to be partially successful in treating 
patients suffering from these diseases, notably asthma and COPD [11, 12, 168, 169]. 
However, patients suffering from IPF, ARDS, and BPD do not overall benefit from 
corticosteroid therapy, despite the fact that these pathologies are characterized by 
inflammatory processes which glucocorticoids should blunt [13, 15-17]. Given that 
TGF-β plays a key pathogenic role in all of these diseases and that corticosteroid use 
has failed to improve the outcome for affected patients, it follows that the interaction of 
TGF-β and glucocorticoid signaling should be investigated.  
 In this study we hypothesized that the TGF-β and glucocorticoid signaling 
pathways interact in vitro and in vivo, and that glucocorticoids may impact TGF-β 
signaling, which may then in turn influence TGF-β-regulated gene expression, thus 
either worsening or improving lung diseases in which TGF-β signaling plays a 
pathogenic role. In order to address this in vitro, we used primary adult fibroblasts, 
primary mouse fibroblasts, primary human pulmonary artery endothelial cells, primary 
human pulmonary arterial vascular smooth muscle cells, H441 human epithelial cells, 
as well as NIH/3T3 mouse fibroblast-like cells. Our aim was to investigate the impact of 
glucocorticoids on: 
 
1) The proximal part of the TGF-β signaling axis by assessing phosphorylation levels 
of Smad1, Smad2, and Smad3 by immunoblot analysis. 
 
2) The distal part of the TGF-β signaling axis by assessing activity of the                 
TGF-β-responsive (CAGA)9 element of the p(CAGA)9-luc, and activity of the                
BMP-responsive element of the pBRE-luc construct by dual luciferase assay as well as 
protein levels of ACTA2 and MYH11. 
 
3) The mRNA and protein expression levels of betaglycan by real-time PCR and 
immunoblot analysis. 
 
4) In vivo TGF-β signaling in the mouse lung, heart, kidney, and liver by assessing 
mRNA expression levels of acvrl1, tgfbr3 and smad1 by real-time PCR analysis, and 
protein expression levels of Tgfbr3, phosphorylated Smad1, total Smad1, 
phosphorylated Smad2 and total Smad2 by immunoblot analysis. 
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3. Materials and methods 
 
3.1 Materials 
 
3.1.1 Equipment 
Adobe Photoshop CS3 Software   Adobe Systems (Inc.), USA 
Buffer dam      BIO-RAD, USA 
Blotting membrane: Trans-Blot Transfer Medium BIO-RAD, USA 
Camera: LAS-4000 cooled CCD   FujiFilm, Japan 
Cell culture hood; SAFE 2020   Thermo Scientific, USA 
Cell culture incubator; HERACELL 150i  Thermo Scientific, USA 
Cell culture flask: 250 ml     Greiner Bio-One, Germany 
Cell culture plates: 6 and 48 well plates  Greiner Bio-One, Germany 
Cellscraper      Sarstedt, Germany 
Centrifuge: Biofuge fresco    Heraeus, Germany 
Centrifuge: Minispin plus    Eppendorf, Germany 
Centro LB 960 microplate luminometer  BERTHOLD TECHNOLOGIES 
GmbH & Co. KG, Germany 
Chromatography paper  WhatmanTM, part of GE Health Care 
Limited, USA 
ELISA reader: Versa max, microplate reader Molecular Devices, Germany 
Electric transformer: Power Pac TM Basic  BIO-RAD, USA  
Falcon: 15, 50 ml     Greiner Bio-One, Germany 
Fridge +4 °C      Bosch, Germany 
Fridge -20 °C      Bosch, Germany 
Fridge -40 °C      Kryotec, Germany 
Fridge -80 °C      Heraeus, Germany 
Glass beakers: 100, 250, 500, 1000 ml  Simax, Czech Republic 
Glass bottles: 500, 1000, 2000 ml   Thermo Fisher Scientific, USA 
Glass plates      BIO-RAD, USA  
Heatblock      VWR, Germany 
Multi Gauge MFC Software    Fujifilm Holding Corporation, Japan 
Nanodrop® spectrophotometer   Peqlab, Germany 
PCR-thermocycler     MJ Research, USA   
Pipettes: 10, 20, 50, 100, 200, 1000 µl  Gilson, France 
Pipetteboy      Eppendorf, Germany 
Pipette tips: 10, 20, 100 µl    Gilson, USA 
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Pipette tips: 200, 1000 µl    Sarstedt, Germany 
Real-time PCR machine: StepOne Plus  Applied Biosystems, USA 
Running chamber: Mini Protean® Tetra Cell  BIO-RAD, USA 
Serological pipettes: 5, 10, 25, 50 ml  Falcon, USA 
Spacer plates: 1.5 mm    BIO-RAD, USA 
Syringe: 0.5, 30 ml     B. Braun, Germany 
Syringe needles: Size 14    B. Braun, Germany 
Timer: Oregon scientific    Roth, Germany 
Transfer chamber: Mini Protean® 3 cell  BIO-RAD, USA 
Tubes: 150 µl, 0.5, 1.5, 2 ml    Sarstedt, Germany 
Vortex machine     Merck Eurolab, Germany 
Water bath: E100     Lauda, Germany 
Well combs: 10, 15     BIO-RAD, USA 
 
3.1.2 Reagents 
Acrylamide solution, Rotiphorese Gel 30  Roth, Germany 
Activin receptor-like kinase (ALK)5 inhibitor: Sigma-Aldrich, Germany 
SB431542 
Albumine, bovine serum    Sigma-Aldrich, Germany 
Ammonium persulfate (APS)    Promega, USA 
Antibiotic/antimycotic mix solution (100×)  Sigma-Aldrich, Germany 
Antibodies (primary, secondary)   Listed in Section 11 
Bradford substrate     BIO-RAD, USA 
Budesonide powder     Sigma-Aldrich, Germany 
Collagenase      Sigma-Aldrich, Germany 
CompleteTM protease inhibitor   Roche, Germany  
Dexamethasone powder    Sigma-Aldrich, Germany 
Dimethyl sulfoxide (DMSO)     Sigma-Aldrich, Germany 
Dithiothreitol (DTT)     Promega, USA 
D-MEM + GlutaMAXTM-I (1×) medium   Life TechnologiesTM, USA 
Dulbecco’s phosphate buffered saline (PBS) 1× Invitrogen, UK 
Dulbecco’s phosphate buffered saline (PBS) 10× Invitrogen, UK 
Ethanol (70%)      VWR, Germany 
Ethanol (100%)     VWR, Germany 
Ethylendinitrilo-N, N, N, N′-tetra-acetic-acid  Promega, USA  
(EDTA) 
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Ethylene glycol-bis (2-amino-ethylether)-N, N, Promega, USA 
N′, N′-tetraacetic-acid (EGTA) 
Fetal calf serum (FCS)     PAA Laboratories, Austria 
Glycine      Roth, Germany 
Hi-Glucose D-MEM     Life TechnologiesTM, USA 
2-(4-2-hydroxyethyl)-piperazinyl-1-ethansulfonate Sigma-Aldrich, Germany 
(HEPES) 
Immunoblot detection kit: SuperSignal® West Thermo Scientific, USA 
Femto Maximum Sensitivity Substrate  
Immunoblot marker: Precision Plus ProteinTM  BIO-RAD, USA 
Dual Color Standards 
Isopropanol       Merck, Germany 
Fluticasone proprionate    Sigma-Aldrich, Germany  
Lipofectamine® 2000     Invitrogen, UK 
Luciferase assay reagent 10-pack    Promega, USA 
Luciferase cell culture lysis 5× reagent   Promega, USA 
Magnesium chloride (MgCl2) solution  Applied Biosystems, USA 
β-mercaptoethanol     Sigma-Aldrich, Germany 
6α-Methylprednisolone    Sigma-Aldrich, Germany 
Methanol      Sigma-Aldrich, Germany 
MnLV reverse transcriptase    Applied Biosystems, USA 
N, N, N′, N′-tetra-methyl-ethylendiamine  Biorad, USA 
(TEMED) 
Non-fat dry milk powder    Roth, Germany 
NP-40       Fluka Biochemika, UK 
Opti-MEM medium      Gibco BRL, Germany 
PCR buffer II      Applied Biosystems, USA 
PCR nucleotide mix     Promega, USA 
Penicillin      Sigma-Aldrich, Germany 
PeqGOLD Total RNA Kit     Peqlab, Germany 
Peqlab/Ceramic Kit 1.4 mm 91-PCS-CK14  Peqlab, Germany 
Platinum® SYBR® Green qPCR SuperMix  Invitrogen, UK 
-UDG-KIT 
Random hexamers     Applied Biosystems, USA 
RNase inhibitor     Applied Biosystems, USA 
RNase-free water     Ambion, Germany 
RPMI-1640 medium     Gibco BRL, Germany 
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Silencer® negative siRNA control   Ambion, Germany 
Sodium dodecyl sulfate (SDS)   Promega, USA 
Sodium chloride     Roth, Germany 
Sodium ortho vanadate    Sigma-Aldrich, Germany 
Streptomycin      Sigma-Aldrich, Germany 
Transforming growth factor (TGF)-β1  R&D Systems, USA 
1.0 M Tris pH 6.8     Roth, Germany 
1.5 M Tris pH 8.8     Roth, Germany 
Trypsin-EDTA      Sigma-Aldrich, Germany 
Tween 20      Sigma-Aldrich, Germany 
 
3.2 Methods 
 
3.2.1 Cell culture 
  
3.2.1.1 NIH/3T3 mouse fibroblast-like cells 
 The NIH/3T3 mouse fibroblast-like cell line (CRL-1658TM, American Type 
Culture Collection) was cultivated in 250 ml tissue culture flasks in 10 ml of D-MEM 
media supplemented with 10% fetal calf serum (FCS) and 10 ml 2-(4-2-hydroxyethyl)-
piperazinyl-1-ethansulfonate (HEPES) and then incubated at 37 °C, 5% CO2, and      
95-100% humidity. After having reached 80-90% confluence, cells were passaged.  
Firstly, media was removed. Cells were then washed with 1× PBS and 
incubated in 3 ml of trypsin/EDTA solution at 37 °C for 3 min. Then, 7 ml of 
supplemented D-MEM media (see above) were added. Before being transferred to a 
new tissue culture flask, cells were diluted in supplemented D-MEM media to a 
concentration of 1:10. For cell culture experiments cells were seeded into 6- or 48-well 
plates in supplemented D-MEM media. 
 
3.2.1.2 Isolation of primary mouse lung fibroblasts 
 In order to isolate primary adult mouse lung fibroblasts for one experiment 
fibroblasts were isolated from two C57BL/6J mice. 
 Mice were sacrificed by an overdose of isoflurane. Before opening the body 
cavities the skin of the mice was soaked in 70% ethanol. After de-gloving the skin 
above the chest the anterior abdomen was cut open using sterile scissors. The 
diaphragm was then carefully punctured from the abdominal side. To avoid blood 
contamination the aorta was cut in the abdominal section. 
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 In order to wash out blood from the pulmonary vascular system the right 
ventricle was cannulated and 10 ml of 1× PBS were administered. Both lung lobes and 
the heart were then cut free from the mediastinum and placed in 15 ml cold 1× PBS in 
a 10-cm dish. These steps were then repeated for a second mouse. Lung lobes and 
hearts from both animals were combined into the 10-cm dish. 
 In order to dissociate lung tissue, the dish containing lung lobes and hearts was 
transferred to a sterile laminar flow hood. The heart was then detached using new 
sterile scissors. Any visible bronchi and mediastinal tissue were then carefully removed 
from both lung lobes. 
 Lung lobes were then placed in a dry 50-ml Falcon tube and minced finely with 
scissors for several minutes. The minced tissue was then left to incubate in 25 ml of 
collagenase (2 ng/ml) preheated to 37 °C on a shaker at 125 revolutions per minute 
(rpm) for 45 min at 37 °C. After titrating the suspension up to 12 times through a 
cannula firmly attached to a 30-ml syringe, tissue chunks were left to settle. The 
suspension was then pipetted through two strainers (70 µm diameter followed by       
40 µm diameter) into a 50-ml Falcon tube and then spun down at 400 g for 8 min at     
4 °C.  
 The cell suspension was then re-suspended in 15 ml of growth media            
(see section 3.2.1.3), seeded in a T-75 flask and left to incubate for 24 h. Cells which 
did not attach in that time were then removed. 
 
Isolation medium 
    Hi Glucose D-MEM media 
    20% FCS 
    1% Penicillin/Streptomycin  
 
3.2.1.3 Cultivating primary mouse lung fibroblasts 
 Primary mouse lung fibroblasts were cultivated like NIH/3T3 mouse     
fibroblast-like cells (see section 3.2.1.1) only using a special growth media consisting of             
Hi Glucose D-MEM containing 10% FCS and 1% Penicillin/Streptomycin. 
 
Growth medium 
    Hi Glucose D-MEM media 
    10% FCS 
    1% Penicillin/Streptomycin 
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3.2.1.4 Primary human lung fibroblasts 
 Primary human lung fibroblasts (CC-2512, Lonza) were cultured following the 
manufacturer’s instructions. 
 
3.2.1.5 Primary human pulmonary artery endothelial cells 
 Primary human pulmonary artery endothelial cells (C0085C,                           
Life Technologies™) were cultured following the manufacturer’s instructions.  
 
3.2.1.6 Primary human pulmonary artery smooth muscle cells 
 Primary human pulmonary artery smooth muscle cells (C0095C, Life 
Technologies™) were cultured following the manufacturer’s instructions. 
 
3.2.1.7 H441 human Clara cell-like airway epithelial cells 
 H441 human Clara cell-like airway epithelial cells (HTB-174TM, American Type 
Culture Collection) were cultured following the manufacturer’s instructions. 
 
3.2.1.8 Experimental cell culture setup 
 Cells were stimulated with corresponding glucocorticoids (dex, 20 nM; met,     
20 nM; bud, 2 nM; flu, 2 nM) for 18 h, where indicated. These concentrations represent 
the mean, circulating, clinically relevant doses when these drugs are employed 
therapeutically [170, 171]. 
In order to determine Smad protein phosphorylation levels, cells were 
additionally stimulated with TGF-β1 (2 ng/ml) for 30 min and the corresponding 
glucocorticoid (total, 18.5 h). When cells were intended for gene expression analysis by 
real-time (RT) polymerase chain reaction (PCR) or for protein expression analysis by 
immunoblot after TGF-β1 stimulation, cells were stimulated in 6-well plates with TGF-β1 
(2 ng/ml) for 12 h and the appropriate glucocorticoid after 18 h of pre-treatment with the 
corresponding glucocorticoid (total, 30 h).  
Assessment of the BMP-responsive element pBRE-luc construct and the    
TGF-β-responsive p(CAGA)9-luc construct induction by dual luciferase assay will be 
discussed separately in section 3.2.13.2. 
 Cell experiments, in which small interfering RNA (siRNA) or overexpressing 
plasmid constructs were employed, will also be discussed separately in sections 3.2.11 
and 3.2.12. 
 
 
 
Materials and methods                                                                                                27 
3.2.2 mRNA isolation 
 In order to isolate mRNA from according cell experiments and mouse organ 
tissues, two different techniques were chosen. 
 
3.2.2.1 mRNA isolation from cells 
 The PeqGOLD Total RNA Kit was used to isolate mRNA from cultured NIH/3T3 
mouse fibroblast-like cells following the manufacturer’s instructions.    
 
3.2.2.2 mRNA isolation from mouse lung, heart, liver, and kidney 
 The Peqlab/Ceramic Kit 1.4 mm 91-PCS-CK14 was used to isolate mRNA from 
whole organ homogenates following the manufacturer’s instructions. 
 
3.2.3 Determining mRNA concentrations 
 According to the Peqlab protocol, 1.5 µl of sample solution was administered to 
Peqlab’s Nanodrop® spectrophotometer to determine the concentration of isolated 
mRNA. 
 
3.2.4 Reverse transcription reaction 
 The reverse transcription reaction is an enzymatic reaction in which the reverse 
transcriptase enzyme synthesizes complementary DNA (cDNA) from template mRNA. 
In order to perform this technique, RNase-free water was added to 1000 ng of the 
according mRNA sample to form a total volume of 20 µl. For denaturation this reaction 
mixture was heated at 70 °C for 10 min before adding 20 µl of mastermix                  
(Table 3.2) and performing the reverse transcription reaction (Table 3.1).  
Table 3.1 Reverse transcription reaction 
Cycle Temperature [°C] Duration [min] Effect 
1 21 10 
Attachment of 
random hexamers 
2 43 75 
Reverse 
transcription 
3 99 5 
Reverse 
transcription 
inactivation 
4 4 Not specific Cooling down 
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Table 3.2 Mastermix composition for the reverse transcription reaction 
 
Mastermix [amount/sample] 
Reagent Volume [µl] 
10× PCR-buffer 4 
MgCl2 solution 8 
PCR nucleotide mix 2 
Random hexamers 2 
RNase inhibitor 1 
MnLV reverse transcriptase 2 
RNase-free water 1 
 
 After amplification, 60 µl of RNase free water were added to each sample to 
form a total volume of 100 µl. Samples were then directly used RT PCR experiments or 
frozen at -20 °C. 
 
3.2.5 Real-time polymerase chain reaction 
 Real-time PCR is a DNA polymerase-driven reaction, in which specific cDNA 
sequences can be amplified with according primers (listed in section 11.3) and 
quantified at the same time. In general, the amplification process consists of three 
steps which form one cycle. 
 
Denaturation: separation of double-stranded DNA into two single strands 
Annealing: primer binding to the according sequence of single DNA strands 
Elongation: synthesis of double-stranded DNA from single-stranded DNA by 
DNA polymerase 
 
In order to quantify relative mRNA levels of a certain gene, a fluorescent dye 
(SYBR® Green I) is added to the RT PCR reaction mix (Table 3.3). SYBR® Green I 
binds directly to double-stranded DNA and its fluorescence intensity can be detected 
specifically after each PCR cycle using the StepOne Plus RT PCR Detection System. 
This fluorescence intensity is proportionate to the amount of amplified DNA of a certain 
gene. The RT PCR reaction program is described in Table 3.4.  
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Table 3.3 Composition of the reaction mix for real-time PCR analysis 
 
Real-time PCR reaction mix [amount/well] 
Reagent Volume [µl] 
Platinum® SYBR® Green qPCR SuperMix-UDG 13 
50 mM MgCl2             1 
10 µM forward primer 0.5 
10 µM reverse primer 0.5 
H2O (autoclaved) 8 
cDNA template 2 
 
 
Table 3.4 Real-time PCR reaction program 
 
Real-time PCR reaction program 
Step Temperature [°C] Duration Cycles 
Initialization/polymerase 
activation 
95 10 min  
Denaturation 95 10 sec 40 
Annealing of primers 59 10 sec 40 
Elongation 72 10 sec 40 
Denaturation 95 1 min 40 
Melting curve 55 - 95 Variable 40 
Cooling down 25 Not specific  
 
 
3.2.6 Determining relative mRNA expression by StepOne Software 
 The StepOne Software was used to determine relative mRNA levels of the 
according gene by following the developer’s instructions. All results were normalized to 
relative mRNA expression levels of the constitutively expressed glyceraldehyde          
3-phosphate dehydrogenase gene (gapdh), which served as an internal control. 
Relative mRNA levels of the according gene were calculated as ∆Ct values             
(∆Ct=Ctinternal control-Cttarget). ∆∆Ct values were calculated (∆∆Ct=∆Cttreated-∆Ctcontrol). All 
ΔΔCt values correspond approximately to the binary logarithm of the fold change. 
Finally, changes in mRNA expression were shown as fold-change using the following 
formula: fold-change=2∆∆Ct values. 
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3.2.7 Protein isolation 
 In order to isolate proteins from cell culture experiments and mouse lung tissue, 
two different techniques were chosen. 
 
3.2.7.1 Protein isolation from cells 
Lysis buffer (Table 3.5) was prepared before isolating proteins from cultured 
cells. Then, 40 µl of sodium ortho vanadate and 160 µl of CompleteTM protease inhibitor 
were then added to 4 ml of lysis buffer and vortexed. After pipetting 150 µl of this 
mixture into each well on a 6-well plate containing cultured cells from experiments, 
cells were detached by using a cellscraper and transferred to a 1.5 ml tube. The cell 
suspension was then incubated on ice for 30 min, during which it was vortexed every   
5 min. After centrifuging, the suspension for 15 min at 13000 rpm and 4 °C, the 
resulting supernatant was used as cell extract, transferred to a 0.5 ml tube and frozen 
at -40 °C. 
 
Table 3.5 Composition of the protein lysis buffer 
 
Protein lysis buffer 
Reagent Concentration 
Tris, pH 7.5 20 mM 
NaCl 150 mM 
Ethylene dinitrilo-N, N, N, N′-tetra-acetic-acid (EDTA) 1 mM 
Ethylene glycol-bis (2-amino-ethylether)-N, N, N′,                     
N′-tetraacetic-acid (EGTA) 
1 mM 
NP-40 0.5% 
 
3.2.7.2 Protein isolation from mouse lungs 
 The Peqlab/Ceramic Kit 1.4 mm 91-PCS-CK14 was used to isolate proteins 
from whole organ homogenates following the manufacturer’s instructions. For cell lysis 
buffer composition see section 3.2.7.1. 
 
3.2.8 Determining protein concentrations 
 Protein concentrations from cell and tissue extracts were                         
spectro-photometrically assessed by using Bradford reagent and an ELISA plate 
reader. Bradford reagent is able to bind to basic and aromatic amino acid residues, 
which results in a change of color. Color intensity depends on the sample protein 
concentration and can be quantified by using a spectrophotometer. Defined 
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concentrations of bovine serum albumin (0.05-0.5 µg/µl) were used to create a 
standard protein curve. The sample protein concentration was determined by 
comparing the sample’s absorbance with the absorbance of the known protein 
concentrations on the standard protein curve. 
 
3.2.9 SDS polyacrylamide gel electrophoresis 
 Protein samples were separated by use of SDS polyacrylamide gel 
electrophoresis. Resolving (Table 3.6) and stacking gels (Table 3.7) were prepared in 
advance. The resolving gel was poured between two glass plates with a spacer in 
between and was left to polymerize for approximately 30 min with isopropanol on top. 
After polymerization, isopropanol was removed. The stacking gel was poured on top of 
the resolving gel and left to polymerize for approximately 30 min, after adding a comb 
to form wells in each gel. Each protein sample contained 25 µl of protein. Then, 10% of     
10× SDS loading buffer was added to each 25 µl protein sample before denaturation at    
95 °C for 10 min. After denaturation, protein samples were pipetted into the according 
wells and electrophoresis was carried out in 1× running buffer (Table 3.8) by applying 
110 V for 90 min. The first well in a gel always contained 10 µl of standard protein 
marker, which served as a protein molecular mass kDa reference. 
 
Table 3.6 Composition of a 10% resolving gel for immunoblot analysis 
 
10% resolving gel [amount/gel] 
Reagent Volume 
H2O 3.2 ml 
30% acrylamide 2.67 ml 
1.5 M Tris, pH 8.8 2 ml 
10% SDS 80 µl 
10% APS 80 µl 
TEMED 8 µl 
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Table 3.7 Composition of a 10% stacking gel for immunoblot analysis 
 
10% stacking gel [amount/gel] 
Reagent Volume 
H2O 3.4 ml 
30% acrylamide 0.8 ml 
1.0 M Tris, pH 6.8 0.6 ml 
10% SDS 50 µl 
10% APS 50 µl 
TEMED 5 µl 
 
 
Table 3.8 Composition of a 10× SDS running buffer for immunoblot analysis 
 
10× SDS running buffer for 1L stock solution 
Reagent Amount [g] 
Tris 30 
Glycine 144 
SDS 10 
 
Bring up the volume to 1 L with distilled water. For 1× running buffer mix 100 ml of   
10× SDS running buffer with 900 ml of distilled water.             
 
3.2.10 Immunoblot analysis 
 Immunoblot analysis is performed in order to detect and visualize certain 
proteins which have been separated by SDS polyacrylamide gel electrophoresis     
(see section 3.2.9).  
    
3.2.10.1 Immunoblotting 
 Immunoblotting was performed after protein separation by SDS polyacrylamide 
gel electrophoresis. Proteins were transferred from a polyacrylamide gel to a 0.2 µm 
thick pure nitrocellulose membrane in 1× transfer buffer (Table 3.9) by applying 110 V 
for 60 min. After transfer, nitrocellulose membranes were blocked in 5% milk-blocking 
buffer (Table 3.10) for 60 min at room temperature. 
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Table 3.9 Composition of a 10× transfer buffer for immunoblot analysis 
 
10× transfer buffer for 1L stock solution 
Reagent Amount [g] 
Tris 24.5 
Glycine 122 
 
 
Bring up the volume to 1 L with distilled water. For a 1× transfer buffer, mix 100 ml of  
10× transfer buffer with 700 ml of distilled water and 200 ml of methanol.  
 
Table 3.10 Composition of a 5% milk-blocking buffer for immunoblot analysis 
 
5% milk-blocking buffer 
Reagent Amount 
Dry milk powder 5 g 
1× PBS washing buffer   100 ml 
 
    
Table 3.11 Composition of a 1× PBS washing buffer for immunoblot analysis 
 
1× PBS washing buffer 
Reagent Volume [ml] 
10× PBS 99 
Tween 20 1 
Distilled water 900 
  
3.2.10.2 Protein visualization 
 After blocking, membranes were incubated with the appropriate primary 
antibody diluted in 5% milk-blocking buffer (Table 3.10) overnight at 4 °C. All primary 
antibodies were used at appropriate concentrations (Table 11.1). Membranes were 
then washed in 1× PBS-washing buffer (Table 3.11) for 30 min, during which the 
washing buffer was changed every 10 min. Next, membranes were incubated with the 
according horseradish peroxidase (HRP)-coupled secondary antibody diluted in 5% 
milk-blocking buffer for 60 min at room temperature. All secondary antibodies were 
used at according concentrations (Table 11.2). After incubation with the second 
antibody, membranes were again washed in 1× PBS washing buffer for 60 min, during 
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which the washing buffer was changed every 10 min. Finally, protein bands were 
visualized using the SuperSignal® West Femto Maximum Sensitivity Substrate 
chemiluminescence detection kit following the manufacturer’s instructions. Membranes 
were then exposed to a digital imaging system (LAS-4000 cooled CCD camera, 
FujiFilm, Japan) for quantitative imaging. Pictures were saved as “.tif” files and 
subsequently processed with the Adobe Photoshop CS3 Software. 
 
3.2.10.3 Membrane stripping 
 In order to reprobe certain membranes with different primary and appropriate 
secondary antibodies, membranes were stripped in 50 ml of stripping buffer              
(Table 3.12) and 347 µl of β-mercaptoethanol at 52 °C for 5 min. Protein visualization 
with the according primary and secondary antibodies was then performed as described 
in section 3.2.10.2. 
 
Table 3.12 Composition of a stripping buffer for immunoblot analysis 
 
Stripping buffer 
Reagent Volume [ml] 
1.0 M Tris, pH 6.8 31 
10% SDS 10 
1× PBS washing buffer 459 
 
3.2.10.4 Determining protein density by Multi Gauge MFC Software 
 The Multi Gauge MFC Software was used to quantify protein density by 
following the developer’s instructions. Statistical analysis of the data was performed as 
described in section 3.2.15. 
 
3.2.11 Transfection of cells with small interfering RNA 
 Specific small interfering RNA oligonucleotides directed against mouse tgfbr3 
and smad1 mRNA (Table 11.4) were employed for transfection of NIH/3T3 mouse 
fibroblast-like cells. Cells were transfected with 200 nM of the according siRNA using 
LipofectaminTM 2000 and OptiMEM. In order to control these experiments, control cells 
were also treated with a non-specific siRNA (Table 11.4) which served as a negative 
control for siRNA-mediated ablation of the according gene mRNA expression. 
OptiMEM was first added to the according amount of siRNA and left to incubate for    
15 min at room temperature. OptiMEM was also added to the according amount of          
LipofectaminTM 2000 and also left to incubate for 15 min at room temperature. These 
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two mixtures were then added together and left to incubate for another 15 min at room 
temperature. After this last incubation period, a certain amount of this mixture was then 
added directly to supplemented D-MEM media (see section 3.2.1.1) and the according 
cells. Before specific treatment with dex, cells were left to incubate with the according 
siRNA for 6 h. Depending on whether cells were intended for Smad protein 
phosphorylation analysis by immunoblot (see section 3.2.11.1) or for induction analysis 
of the appropriate promoter by dual luciferase assay analysis (see section 3.2.13.3), 
different protocols were applied. 
 
3.2.11.1 Experimental cell culture setup for knock-down experiments 
 After a 6-h incubation period with specific siRNA alone, cells remained 
untreated or stimulated with dex (20 nM) for 18 h, during which time siRNA was not 
removed (total mRNA ablation time, 24 h). After this 24-h mRNA ablation period, media 
was changed and cells intended for Smad protein phosphorylation analysis by 
immunoblot or induction analysis of the according promoter cells by dual luciferase 
assay analysis were stimulated as described in section 3.2.1.1. 
 
3.2.12 Transfection of cells with TGFBR3-expressing plasmid constructs 
The human TGFBR3 gene, which was amplified from human lung cDNA, was 
cloned into the pIRES hrGFPII plasmid vector (supplied by Gero Niess). Cells were 
transfected with these plasmids using LipofectaminTM 2000 and OptiMEM. In order to 
control these experiments, cells were also treated with empty pIRES hrGFPII plasmids 
to serve as a negative control. Firstly, OptiMEM was added to plasmids and left to 
incubate for 15 min at room temperature. OptiMEM was also added to the appropriate 
amount of LipofectaminTM 2000 and also left to incubate for 15 min at room 
temperature. These two mixtures were then added together and left to incubate for 
another 15 min at room temperature. After this last incubation period, a certain amount 
of this mixture was then directly added to supplemented D-MEM media (see section 
3.2.1.1) and according cells. Before specific treatment with TGF-β1 (2 ng/ml), cells 
were left to incubate with appropriate plasmids for 6 h. Depending on whether cells 
were intended for Smad protein phosphorylation analysis by immunoblot (see section 
3.2.12.1) or for induction analysis of the appropriate promoter by dual luciferase assay 
analysis (see section 3.2.13.4), different protocols were applied. 
 
3.2.12.1 Experimental cell culture setup for overexpression experiments 
For Smad1 protein phosphorylation analysis, transfected cells were then 
stimulated with TGF-β1 (2 ng/ml) for 30 min. Cells which were intended for induction 
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analysis of the appropriate promoter by dual luciferase assay analysis, were treated as 
described in section 3.2.1.1. 
 
3.2.13 Dual luciferase ratio assay analysis 
 The dual luciferase ratio (DLR) assay analysis is a technique to assess 
promoter induction of a certain gene which is incorporated into an according plasmid. 
Therefore, this technique is able to detect the activity of according signaling pathways. 
In principle, the according gene promoter is cloned into a special plasmid construct 
upstream of the firefly luciferase gene, which encodes for the luciferase enzyme. This 
special plasmid is then transfected into cells. The luciferase enzyme activity can be 
measured by employing a special fluorescence luciferase assay reagent substrate 
(Promega, USA). Fluorescence, which is emitted during the luciferase enzyme-driven 
reaction can be detected with a microplate luminometer. Fluorescence intensity is 
proportional to promoter induction of the firefly luciferase gene and, therefore, to the 
signaling pathway activity of interest. In order to control this experiment, the 
constitutively-active Renillla luciferase simian virus 40 (SV40)-based plasmid construct 
is simultaneously transfected into cells containing the firefly luciferase reporter to serve 
as a reference. This Renilla luciferase gene encodes for the luciferase enzyme and is 
constitutively active. This enzyme activity can also be measured by employing a 
special fluorescence luciferase substrate (Promega, USA). The fluorescence which is 
emitted during this enzymatic reaction can also be detected with a microplate 
luminometer. After transfecting cells with according plasmids (see section 3.2.13.1), 
cells were stimulated according to protocol (see sections, 3.2.13.2, 3.2.13.3 and 
3.2.13.4). For normalization, all raw firefly values were then divided by the 
corresponding Renilla values from the same cell lysate.  
  
3.2.13.1 Transfection of cells with corresponding plasmids 
 After passaging, the cells intended for dual luciferase assay experiments were 
pipetted into the wells of a 48-well cell culture plate and left to become confluent for   
24 h. OptiMEM was first added to a suspension containing the firefly luciferase plasmid 
construct (p(CAGA)9-luc construct or pBRE-luc construct containing the gene promoter 
of interest and the Renilla luciferase reporter plasmid construct to form a total volume 
of 50 µl. This suspension was mixed carefully and left to incubate for 15 min. Then, 
49.25 µl of OptiMEM were also added to 0.75 µl of LipofectaminTM 2000 and also left to 
incubate for 15 min at room temperature. These two mixtures were then added 
together to form a total volume of 100 µl, mixed carefully and left to incubate for 
another 20 min at room temperature. Media was then removed from each well and 
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cells were washed with ice cold 1× PBS solution. After removing 1× PBS solution from 
each well, 100 µl of transfection mixture was pipetted into each well and left to incubate 
for 6 h at 37 °C, 5% CO2, and 95-100% humidity. After a 6-h incubation period, the 
transfection mixture was removed from each well and cells were stimulated according 
to protocol (see sections 3.2.13.2, 3.2.13.3 and 3.2.13.4). In order to control this 
experiment, cells on one 48-well cell culture plate were also transfected with a 
constitutively-active firefly luciferase plasmid construct and the constitutively-active 
Renilla luciferase plasmid construct as positive control. Furthermore, cells were 
transfected with a constitutively inactive-firefly luciferase plasmid construct and the 
constitutively-active Renilla luciferase plasmid construct serving as a negative control. 
Another group of cells was transfected with the constitutively-active Renilla luciferase 
plasmid construct only, another group with OptiMEM and LipofectaminTM 2000 only, 
and the last group did not receive any transfection reagents. 
 
3.2.13.2 Experimental cell culture setup for dual luciferase assay 
 After a 6-h incubation period, transfection reagents containing corresponding 
plasmid constructs were removed from all wells. Cells then remained untreated or were 
stimulated with the corresponding glucocorticoid (concentration as indicated) for 18 h. 
After this 18-h pre-treatment with the appropriate glucocorticoid, untreated cells were 
either stimulated with TGF-β1 (2 ng/ml) for 12 h (total, 30 h) or remained unstimulated 
at 37 °C, 5% CO2, and 95-100% humidity. Pre-treated cells were either stimulated with 
the corresponding glucocorticoid or with TGF-β1 and the same glucocorticoid for 12 h 
(total, 30 h) at 37 °C, 5% CO2, and 95-100% humidity. After drug and hormone 
treatment, cells were washed with ice cold 1× PBS solution and either directly used for 
dual luciferase experiments or frozen at -80 °C. 
 
3.2.13.3 Experimental cell culture setup with small interfering RNA 
 A different protocol was applied for cells intended for analysis of promoter 
induction by dual luciferase assay and also employing siRNA for mRNA ablation. After 
a 6-h incubation period, transfection reagents containing according plasmid constructs 
were removed from all wells. Next, the corresponding siRNA was prepared as 
described as in section 3.2.11, diluted in supplemented D-MEM media (see section 
3.2.1.1) to the indicated concentrations, added to the according cells and left to 
incubate for 6 h at 37 °C, 5% CO2, and 95-100% humidity. Drug and hormone 
treatment was then performed as explained in section 3.2.13.2. 
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3.2.13.4 Experimental cell culture setup with TGFBR3-expressing plasmids 
 A different protocol was applied for cells intended for analysis of promoter 
induction analysis by dual luciferase assay and also employing TGFBR3 
overexpressing plasmids. After a 6-h incubation period, transfection reagents 
containing according plasmid constructs were removed from all wells. The TGFBR3 
overexpressing constructs were then prepared as described as in section 3.2.12, 
diluted in supplemented D-MEM media (see section 3.2.1.1) to the indicated 
concentrations, added to the according cells, and left to incubate for 6 h at 37 °C,      
5% CO2, and  95-100% humidity. Drug and hormone treatment was then performed as 
explained in section 3.2.13.2. 
 
3.2.13.5 Cell lysis 
 For cell lysis 5 ml of the 5× Luciferase Lysis reagent (Promega, USA) were 
diluted in 20 ml of RNase-free water. Next, 100 µl of this lysis solution were then 
pipetted into each well containing transfected cells intended for analysis of luciferase 
activity and left to incubate for 20 min on a shaker at room temperature. 
  
3.2.13.6 Determining luciferase activity 
 Lysed cells were then analyzed for luciferase activity by using the Luciferase 
assay reagent pack (Promega, USA) and the Centro LB 960 microplate luminometer 
(BERTHOLD TECHNOLOGIES GmbH & Co. KG, Germany) following the 
manufacturer’s instructions. Raw values were treated as described in section 3.2.13. 
Statistical data analysis was performed as described in section 3.2.15. 
 
3.2.14 Animal studies 
 All animal experiments were approved by institutional and national authorities 
under approval number B2/331 from the Regierungspräsidium Darmstadt [housing the 
Institutional Animal Care and Use Committee]. 
  
3.2.14.1 Pulmonary effects of dexamethasone in mice 
 In order to assess the impact of glucocorticoid administration on TGF-β 
signaling in vivo in the mouse lung, 50 mg of dex powder were dissolved in 10 ml of 
DMSO and 10 ml of 1× PBS (vehicle) to a concentration of 2.5 mg/ml. Twelve wild-type 
female C57BL/J6 mice were used for this animal experiment. Each mouse was          
11 weeks old and weighed approximately 20 g. Then, six mice received a 0.2 ml 
intraperitoneal injection of dex and vehicle at 10 mg/kg bodyweight, while six control 
mice received a 0.2 ml intraperitoneal injection of vehicle only. Next, 24 h after drug 
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administration mice were sacrificed using an overdose of isoflurane, and lung lobes, 
the liver, the heart, and kidneys were explanted for mRNA and protein isolation. 
 
3.2.14.2 Organ storage 
 After explantation, organs were immediately shock-frozen in liquid nitrogen and 
stored at -80 °C. 
 
3.2.15 Statistical analysis 
 Data are indicated as mean ± standard deviation (S.D.). Statistical comparisons 
were made with an unpaired Student’s t-test and by one-way ANOVA, followed by a 
Bonferroni post-hoc test, to evaluate whether differences between means were 
significant.
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4. Results 
 
4.1 Glucocorticoids inhibit classical Tgfbr1/Smad2/3 signaling in NIH/3T3 mouse 
fibroblast-like cells 
 
4.1.1 p(CAGA)9 induction analysis by dual luciferase assay 
The interaction of glucocorticoid and TGF-β signaling was first analyzed by 
induction analysis of the (CAGA)9 Smad3-binding element which is common in genes 
regulated by the TGF-β/Tgfbr1/Smad2/3 pathway. In order to analyze induction the 
luminescence-based dual luciferase assay was employed (Fig. 4.1).    
                        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.1. Glucocorticoids inhibit transforming growth factor-β1-induced activation of the p(CAGA)9-luc 
promoter construct. The TGF-β1-responsive p(CAGA)9-luc promoter construct was transfected into NIH/3T3 cells 
for a duration of 6 h. Then transfected cells were stimulated with dexamethasone [dex] at a concentration of 20 nM 
(A), methylprednisolone [met] at a concentration of 20 nM (B), budesonide [bud] at a concentration of 2 nM (C), and 
fluticasone  [flu] at a concentration of 2 nM (D) for a period of 18 h. Then one group of cells was stimulated with 
TGF-β1 only at a concentration of 2 ng/ml for a duration of 12 h. Glucocorticoid-treated cells were either treated with 
the same glucocorticoid or the same glucocorticoid and TGF-β1 at a concentration of 2 ng/ml for 12 h. Media was 
then removed, cells were washed in ice cold 1× PBS, and finally incubated in lysis buffer.  A dual luciferase assay 
was employed to assess activity of the p(CAGA)9-luc construct. Data are presented as mean ± S.D. Experiments 
were repeated six times. One-way ANOVA and Bonferroni post-hoc analyses were used to analyze whether 
differences between groups were significant. P-values <0.05 were considered significant. 
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Stimulation with TGF-β1 stimulation for 12 h resulted in strong activation of the 
(CAGA)9 element of the p(CAGA)9-luc construct (Fig. 4.1A, B, C, D) when comparing 
the first and third bar. Glucocorticoid treatment with indicated concentrations did not 
affect activation of the p(CAGA)9 element (Fig. 4.1A, B, C, D) when comparing the first 
and second bar. Interestingly, when comparing the third and fourth bar, treatment with 
dex in the presence of TGF-β1 inhibited the activation of the p(CAGA)9 element     
(FigA. 4.1). Methylprednisolone, bud, and flu all had a similar effect on TGF-β1-induced 
Tgfbr1/Smad2/3 pathway activation. Overall, this indicates that corticosteroids are able 
to effectively inhibit activation of the p(CAGA)9 element via Tgfbr1/Smad2/3 signaling.    
 
4.1.2 Immunoblot analysis of phospho-Smad2 and phospho-Smad3 
After examining distal effects along the Tgfbr1/Smad2/3 axis, the impact of 
corticosteroids on proximal Smad2 and Smad3 activation was assessed by immunoblot 
analysis (Fig. 4.2).  
 
 
Fig. 4.2 Corticosteroids inhibit transforming growth factor-β1-induced phosphorylation of Smad2 and Smad3. 
Cells were stimulated with dexamethasone [dex] at a concentration of 20 nM for 18 h. Then one group of cells was 
stimulated with TGF-β1 only at a concentration of 2 ng/ml for 30 min. Dexamethasone-treated cells were either then 
again treated with dexamethasone or dexamethasone in combination with TGF-β1 at a concentration of 2 ng/ml for a 
duration of 30 min. Media was then removed, cells were washed in ice cold 1× PBS, and finally incubated in lysis buffer. 
Proteins were then isolated in order to assess Smad2 and Smad3 phosphorylation by immunoblot analysis (A). 
Densitometric analysis was used to quantify Smad2 and Smad3 phosphorylation (B,C). Data in B and C are presented 
as mean ± S.D. Experiments were repeated three times. An unpaired Student’s t-test was used to analyze whether 
differences between groups were significant. P-values <0.05 were considered significant.  
 
After activation by TGF-β1, Tgfbr1 phosphorylates the intracellular signaling 
messengers Smad2 and Smad3. Stimulation of NIH/3T3 cells with TGF-β1 for 30 min 
resulted in strong phosphorylation of Smad2 and Smad3. This was evident when 
comparing the first and third lane in Fig. 4.2A. Dexamethasone treatment of NIH/3T3 
alone already resulted in less phosphorylation of Smad2 and Smad3 which was visible 
when comparing the first and second lane in Fig. 4.2A. After pre-treatment with dex, 
when comparing lane three and lane four in Fig. 4.2A, TGF-β1-induced activation of 
Smad2 and Smad3 was significantly less pronounced. Smad2 (Fig. 4.2B) and Smad3 
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(Fig. 4.2C) phosphorylation were quantified by densitometric analysis. Overall, these 
immunoblot data taken together with the dual luciferase analysis (Fig. 4.1) suggest that 
glucocorticoids inhibit the proximal and distal part of the Tgfbr1/Smad2/3 signaling 
pathway in NIH/3T3 cells.    
 
4.2 Dexamethasone increases relative tgfbr3 mRNA expression levels in NIH/3T3 
mouse fibroblast-like cells  
 Dexamethasone, met, bud, and flu were all able to block activation of the 
Tgfbr1/Smad2/3 signaling pathway. In order to explain this observation the impact of 
dexamethasone and TGF-β1 on different TGF-β receptor mRNA expression levels was 
assessed by RT PCR (Fig. 4.3).     
 
 
Fig. 4.3 Glucocorticoids induce relative tgfbr3 mRNA expression levels in NIH/3T3 mouse fibroblast-like cells. In 
the first experiment cells were treated with dexamethasone [dex] only for 18 h at a concentration of 20 nM (A). 
Experiments were repeated 4 times. In a second experiment cells were treated with dexamethasone at a concentration 
of 20 nM for a duration of 18 h (B). Then one group of cells was stimulated with TGF-β1 only at a concentration of          
2 ng/ml for a duration of 12 h. Dexamethasone-treated cells were either then again treated with dexamethasone or 
dexamethasone in combination with TGF-β1 at a concentration of 2 ng/ml for a period of 12 h (B). Media was then 
removed, cells were washed in ice cold 1× PBS, and finally incubated in lysis buffer. Relative mRNA expression was 
assessed by RT PCR in order to assess levels of tgfbr1, tgfbr2, tgfbr3, and acvrl1. These experiments were repeated 
four times. Data are presented as mean ± S.D. An unpaired Student’s t-test was used to analyze whether differences 
between groups were significant. P-values <0.05 were considered significant. * indicates a P-value <0.05. 
 
Cells treated with dex for a duration of 18 h demonstrated increased relative 
tgfbr3 mRNA expression levels (Fig. 4.3A). In a second experiment dex in the presence 
of TGF-β1 was still able to increase tgfbr3 mRNA expression levels (Fig. 4.3B). Also, 
cells receiving dex treatment only demonstrated increased relative acvrl1 expression 
levels after 18 h (Fig. 4.3A) and 30 h (Fig. 4.3B). This significant increase was lost in 
the presence of TGF-β1 (Fig. 4.3B). Relative tgfbr1 and tgfbr2 mRNA expression levels 
remained unaffected by dex and TGF-β1 treatment (Fig. 4.3A,B). Taken together, dex, 
even in the presence of TGF-β1 (2 ng/ml), increased tgfbr3 mRNA levels in NIH/3T3 
mouse fibroblast-like cells. 
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Fig. 4.4 p(CAGA)9 induction analysis by dual luciferase assay after tgfbr3 knock-down. The                      
TGF-β1-responsive p(CAGA)9-luc promoter construct was transfected into NIH/3T3 cells for a duration of 6 h. Next, 
tgfbr3 siRNA at a concentration of 200 nM and indicated by black bars (A) and scrambled siRNA at a concentration 
of 200 nM and indicated by white bars (A) were transfected into these cells for another 6-h period. Transfected cells 
were stimulated with dexamethasone [dex] at a concentration of 20 nM (A) for a period of 18 h. Then one group of 
cells was stimulated with TGF-β1 only at a concentration of 2 ng/ml for a duration of 12 h.                     
Dexamethasone-treated cells were either then treated with dexamethasone again or dexamethasone in combination 
with TGF-β1 at a concentration of 2 ng/ml for another 12 h. Media was then removed, cells were washed in ice cold 
1× PBS, and finally incubated in lysis buffer. A dual luciferase assay was used to assess activity of the      
p(CAGA)9-luc promoter construct. Data are presented as mean ± S.D. Experiments were repeated six times.       
One-way ANOVA and Bonferroni post-hoc analyses were used to analyze whether differences between groups 
were significant. P-values <0.05 were considered significant. 
 
 
 
4.3 Glucocorticoids recruit Tgfbr3 to shift TGF-β signaling from the 
Tgfbr1/Smad2/3 axis to the Acvrl1/Smad1 axis   
 
4.3.1 p(CAGA)9 induction analysis by dual luciferase assay after tgfbr3        
knock-down 
 Dexamethasone upregulated tgfbr3 mRNA expression in NIH/3T3 cells after 18 
and 30 h (Fig. 4.3A,B). This was paralleled by increased Tgfbr3 protein expression in 
the same cell type after dex treatment when comparing lane one and lane three in   
Fig. 4.5A. In order to assess the functional relevance of Tgfbr3 on dex effects on 
Tgfbr1/Smad2/3 pathway activity a tgfbr3 knock-down experiment was performed 
employing siRNA directed against tgfbr3 mRNA (Fig. 4.4A).  
                       
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Transforming growth factor-β1 strongly induced p(CAGA)9 element activity    
(Fig. 4.4A) which is visible when analyzing the first and third bar. When Tgfbr3 
expression was knocked down, the effect of TGF-β1 on p(CAGA)9 element activity was 
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even stronger (Fig. 4.4A). This is visible when comparing the fifth and sixth bar. This 
indicates that Tgfbr3 may act inhibitory on Tgfbr1/Smad2/3 signaling in this cell type. 
As demonstrated in the first experiment (Fig. 4.1A), dex significantly reduced         
TGF-β1-induced p(CAGA)9 element activity (Fig. 4.4A). However, this blocking effect of 
dex was lost in cells lacking Tgfbr3 indicating that this accessory receptor may mediate 
the effects of dex on Tgfbr1/Smad2/3 pathway activity when comparing bar seven and 
bar eight in Fig. 4.4A.             
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Fig. 4.5 Immunoblot analysis of phospho-Smad1/5/8, phospho-Smad2, and phospho-Smad3 after tgfbr3 
knock-down. Knock-down tgfbr3 siRNA at a concentration of 200 nM and indicated by black bars (A) and scrambled 
siRNA at a concentration of 200 nM and indicated by white bars (A) were transfected into NIH/3T3 cells for a duration 
of 6 h. Transfected cells were stimulated with dexamethasone [dex] at a concentration of 20 nM (A) for a period of    
18 h. Then one group of cells was stimulated with TGF-β1 only at a concentration of 2 ng/ml for a duration 30 min.                     
Dexamethasone-treated cells were either then treated with dexamethasone again or dexamethasone in combination 
with TGF-β1 at a concentration of 2 ng/ml for another 30 min. Media was then removed, cells were washed in ice cold 
1× PBS, and finally incubated in lysis buffer. Proteins were then isolated in order to assess Smad1, Smad2, and 
Smad3 phosphorylation as well as total Smad1, Smad2, Smad3, and Tgfbr3 protein levels by immunoblot analysis 
(A). Densitometric analysis was used to quantify immunoblot bands (B,C,D). Data in B, C, and D are presented as 
mean ± S.D. Experiments were repeated three times. An unpaired Student’s t-test was used to analyze whether 
differences between groups were significant. P-values <0.05 were considered significant. Significances in B were 
calculated with an unpaired Student’s t-test comparing dexamethasone and TGF-β1-induced protein induction with 
non-treated cells. 
 
4.3.2 Immunoblot analysis of phospho-Smad1/5/8, phospho-Smad2, and      
phospho-Smad3 after tgfbr3 knock-down 
Next, the proximal aspects of Tgfbr1/Smad2/3 and Acvrl1/Smad1 signaling 
were investigated in the context of a tgfbr3 knock-down (Fig. 4.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Phosphorylation of Smad1, Smad2, and Smad3 were analyzed by immunoblot 
(Fig. 4.5A) and quantified in three individual experiments. Knock-down efficiency was 
assessed by analyzing Tgfbr3 protein expression in cells transfected with siRNA 
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directed against tgfbr3 mRNA and quantified. Transforming growth factor-β1 strongly 
phosphorylated Smad2 and Smad3 after 30 min (Fig. 4.5A). This effect was visible 
when comparing the first and fifth lane. In lane six cells lacking Tgfbr3 demonstrated 
pronounced activation of Smad2 and Smad3 (Fig. 4.5A). This indicates that Tgfbr3 acts 
antagonistically to Tgfbr1/Smad2/3 in NIH/3T3 cells. Furthermore, the inhibitory effect 
of dex on aTGF-β1-induced phosphorylation of Smad2 and Smad3 was lost in the 
absence of Tgfbr3 (Fig. 4.5A). This became clear when comparing lane seven and lane 
eight. This indicates that dex requires the accessory Tgfbr3 to inhibit the                  
Tgfbr1/Smad2/3 signaling pathway. 
Interestingly, in lane three dex induced Smad1 phosphorylation (Fig. 4.5A). 
Smad1 is activated by Acvrl1 and, therefore, represents an alternative TGF-β signaling 
route. Transforming growth factor-β1 alone also stimulated Smad1 phosphorylation 
(Fig. 4.5A). This was visible when comparing lane five with lane one. This effect was 
potentiated in the presence of dex (Fig. 4.5A) which was visible when comparing lane 
seven with the first, third, and fifth lane. In cells lacking Tgfbr3, less Smad1 
phosphorylation was observed in all cases (Fig. 4.5A). This indicates that dex uses 
Tgfbr3 to redirect TGF-β signaling from the Tgfbr1/Smad2/3 pathway to the 
Acvrl1/Smad1 pathway.  
 
4.4 Overexpression of TGFBR3 activates the Acvrl1/Smad1 axis  
 
4.4.1 Immunoblot analysis of phospho-Smad1/5/8 after TGFBR3 overexpression 
In order to test whether Tgfbr3 alone was able to activate the Acvrl1/Smad1 
signaling axis, a plasmid construct expressing TGFBR3 was transfected into NIH/3T3 
cells (Fig. 4.6A). Overexpression of TGFBR3 in this cell type dose-dependently 
resulted in increased Smad1 phosphorylation. This was visible when analyzing lanes 
seven, nine, and eleven and lanes one, three, and five (Fig. 4.6A). In combination with 
TGF-β1 this effect could even be potentiated (Fig. 4.6A). This became evident by 
comparing lane eight with lane seven, lanes ten with lane nine, and lane twelve with      
lane eleven. Furthermore, TGFBR3 overexpression resulted in a similar protein 
increase as seen after stimulation with dex (Fig. 4.5A). This proves that this increase in 
Tgfbr3 protein levels is enough to activate the Acvrl1/Smad1 signaling pathway.     
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Fig. 4.6 Immunoblot analysis of phospho-Smad1/5/8 after TGFBR3 overexpression. NIH/3T3 mouse          
fibroblast-like cells were transfected with a plasmid construct overexpressing TGFBR3 (pIRES::TGFBR3) and an 
empty vector construct (pIRES) serving as control (A). For this experiment 3 different doses were used. Cells were 
then partly stimulated with TGF-β1 [2 ng/ml] for 30 min. Media was then removed, cells were washed in ice cold        
1× PBS, and finally incubated in lysis buffer. Proteins were then isolated in order to assess Smad1/5/8 
phosphorylation by immunoblot analysis. Immunoblot bands were then quantified by densitometric analysis in B. Data 
in B are presented as mean ± S.D. Experiments were repeated three times. An unpaired Student’s t-test was used to 
analyze whether differences between groups were significant. P-values <0.05 were considered significant. In this case            
P-values in B compare mean values of cells transfected with the TGFBR3-expressing construct and cells transfected 
with the empty vector.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.4.2 pBRE induction analysis by dual luciferase assay after TGFBR3 
overexpression 
 Overexpression of TGFBR3 alone and in combination with TGF-β1 resulted in 
increased proximal activation of the Acvrl1/Smad1 axis which was reflected by 
increased Smad1 phosphorylation. The next experiment was aimed at assessing distal 
activation of the Acvrl1/Smad1 pathway (Fig. 4.7A). For this, a plasmid containing the 
Smad1-responsive pBRE was transfected into NIH/3T3 cells after these cells were 
transfected with the TGFBR3-expressing construct (pIRES::TGFBR3; 2 µg) or the 
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Fig. 4.7 p(BRE) induction analysis by dual luciferase assay after TGFBR3 overexpression.  NIH/3T3 mouse 
fibroblast-like cells were transfected with the pBRE-luc promoter construct for 6 h. Next, TGFBR3-expressing plasmids 
(pIRES::TGFBR3) and empty vector constructs (pIRES) were transfected into these cells. Media was then removed, 
cells were washed in ice cold 1× PBS, and finally incubated in lysis buffer. A dual luciferase assay was used to assess 
the activation of the pBRE-luc plasmid construct. Data are presented as mean ± S.D. This experiment was repeated   
six times. An unpaired Student’s t-test was used to analyze whether differences between groups were significant.     
P-values <0.05 were considered significant.  
 
pIRES empty vector construct serving as control. Overexpression of TGFBR3 resulted 
in increased pBRE-luc construct activity indicating increased downstream activity of the 
Acvrl1/Smad1 pathway. Overall, overexpression of TGFBR3 in NIH/3T3 cells resulted 
in increased proximal and distal activation of the Acvrl1/Smad1 pathway suggesting 
that this type III TGF-β co-receptor favors this TGF-β pathway in this cell type.  
 
 
 
 
 
 
 
 
 
 
 
  
 
4.5 Glucocorticoids also require Smad1 to effectively inhibit Tgfbr1/Smad2/3 
signaling  
 
4.5.1 p(CAGA)9 induction analysis by dual luciferase assay after smad1       
knock-down  
Dexamethasone and TGF-β1 treatment as well as overexpression of TGFBR3 
all resulted in increased Smad1 phosphorylation (Fig. 4.5A and Fig. 4.6A). This 
suggested that this intracellular messenger might also be involved in the ability of 
glucocorticoids to redirect TGF-β signaling to the Acvrl1/Smad1 axis. Therefore, the 
next experiment was aimed at examining the effects of dex and TGF-β1 on downstream 
activity of the Tgfbr1/Smad2 pathway in the absence of Smad1 by employing siRNA 
directed against smad1 mRNA (Fig. 4.8A). As previously demonstrated, TGF-β1 
increased p(CAGA)9 activity when comparing bar five and bar one in Fig. 4.8A. Similar 
to the results obtained from the tgfbr3 knock-down experiment (Fig. 4.5A) the effect of 
TGF-β1 stimulation on p(CAGA)9 activity in the absence of smad1 was stronger 
indicating a negative regulatory effect of Smad1 on Tgfbr1/Smad2/3 signaling. This 
Results                                                                                                                          49 
Fig. 4.8 p(CAGA)9 induction analysis by dual luciferase assay after smad1 knock-down. Knock-down smad1 
siRNA at a concentration of 200 nM and indicated by black bars (A) and scrambled siRNA at a concentration of   
200 nM and indicated by white bars (A) were transfected into NIH/3T3 cells for a duration of 6 h. Transfected cells 
were stimulated with dexamethasone [dex] at a concentration of 20 nM (A) for a period of 18 h. Then one group of 
cells was stimulated with TGF-β1 only at a concentration of 2 ng/ml for a duration of 12 h. Dexamethasone-treated 
cells were either then treated with dexamethasone again or dexamethasone in combination with TGF-β1 at a 
concentration of 2 ng/ml for another 12 h. Media was then removed, cells were washed in ice cold 1× PBS, and 
finally incubated in lysis buffer. A dual luciferase assay was used to assess activity of the p(CAGA)9-luc promoter 
construct. Data are presented as mean ± S.D. Experiments were repeated six times. One-way ANOVA and 
Bonferroni post-hoc analyses were used to analyze whether differences between groups were significant.              
P-values <0.05 were considered significant. 
  
  
  
 
was evident when comparing bar five with bar six in Fig. 4.8A. As expected dex 
decreased TGF-β1-induced p(CAGA)9 activity when comparing bar five with bar seven 
in Fig. 4.8A. This inhibitory effect was lost in smad1-deficient cells indicating that dex 
also requires Smad1 in order to inhibit Tgrbr1/Smad2/3 downstream activity.     
 
 
 
 
 
 
 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
4.5.2 Immunoblot analysis of phospho-Smad2 after smad1 knock-down 
In the previous experiment smad1-deficient cells demonstrated increased 
Tgfbr1/Smad2/3 signaling after TGF-β1 stimulation. Furthermore, this phenomenon 
could not be inhibited by dex treatment in cells lacking smad1. The next experiment 
was aimed at analyzing proximal signaling activity in the context of a smad1         
knock-down (Fig. 4.9). As expected TGF-β1 stimulation for 30 min resulted in increased 
phosphorylation of Smad2. This was evident when comparing lane five with lane one in 
Fig. 4.9A. This effect, similar to the results obtained from the tgfbr3 knock-down 
experiment, was more pronounced in smad1-deficient cells indicating antagonistic 
effects of Smad1 on Smad2 phosphorylation when comparing lane five with lane six in 
Fig. 4.9A. Dexamethasone inhibited TGF-β1-induced phosphorylation of Smad2 which 
is visible when comparing lane seven and lane nine (Fig. 4.9A). However, this blocking 
Results                                                                                                                          50 
Fig. 4.9 Immunoblot analysis of phospho-Smad2 after smad1 knock-down. Knock-down smad1 siRNA at a 
concentration of 200 nM and indicated by black bars (A) and scrambled siRNA at a concentration of 200 nM and 
indicated by white bars (A) were transfected into NIH/3T3 cells for a duration of 6 h. Transfected cells were 
stimulated with dexamethasone [dex] at a concentration of 20 nM (A) for a period of 18 h. Then one group of cells 
was stimulated with TGF-β1 only at a concentration of 2 ng/ml for a duration of 30 min. Dexamethasone-treated cells 
were either then treated with dexamethasone again or dexamethasone in combination with TGF-β1 at a 
concentration of 2 ng/ml for another 30 min. Media was then removed, cells were washed in ice cold 1× PBS, and 
finally incubated in lysis buffer. Proteins were then isolated in order to assess Smad1 and Smad2 phosphorylation 
as well as total Smad1 and total Smad2 protein levels by immunoblot analysis (A). Densitometric analysis was used 
to quantify immunoblot bands (B). Data in B are presented as mean ± S.D. Experiments were repeated three times. 
An unpaired Student’s t-test was used to analyze whether differences between the two groups were significant.     
P-values <0.05 were considered significant. 
effect of dex was lost in smad1-deficient cells (Fig. 4.9A). This becomes visible when 
comparing lane eight and lane seven (Fig. 4.9A). In conclusion, these data suggest that 
Smad1 antagonizes the Tgfbr1/Smad2/3 pathway. Furthermore, dex recruits Smad1 to 
block Tgfbr1/Smad2/3 activity.   
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Fig. 4.10 Dexamethasone modulates Tgfbr1/Smad2/3 and Acvrl1/Smad1 signaling in primary mouse lung 
fibroblasts. Primary mouse lung fibroblasts were isolated from mouse lungs as described in section 3.2.1.2. A, The 
TGF-β1-responsive p(CAGA)9-luc promoter construct was transfected into these isolated cells for a duration of  6 h. 
Then transfected cells were stimulated with dexamethasone [dex] at a concentration of 20 nM (A) for a period of 18 
h. Then one group of cells was stimulated with TGF-β1 only at a concentration of 2 ng/ml for a duration of 12 h. 
Dexamethasone-treated cells were either treated with dexamethasone or dexamethasone and TGF-β1 at a 
concentration of 2 ng/ml for 12 h. A dual luciferase assay was employed to assess activity of the p(CAGA)9-luc 
promoter construct. Data are presented as mean ± S.D. Experiments were repeated three times. One-way ANOVA 
and Bonferroni post-hoc analyses were used to analyze whether differences between groups were significant.       
P-values <0.05 were considered significant. B, Cells were stimulated with dexamethasone [dex] at a concentration 
of 20 nM for 18 h. Then one group of cells was stimulated with TGF-β1 only at a concentration of 2 ng/ml for 30 min.    
Dexamethasone-treated cells were either then again treated with dexamethasone or dexamethasone in combination 
with TGF-β1 at a concentration of 2 ng/ml for a duration of 30 min. Media was then removed, cells were washed in 
ice cold 1× PBS, and finally incubated in lysis buffer. Proteins were then isolated in order to assess Smad2 and 
Smad3 phosphorylation by immunoblot analysis.   
4.6 Effect of dexamethasone on primary lung fibroblasts 
In NIH/3T3 mouse fibroblast-like cells dex inhibited proximal and distal 
Tgfbr1/Smad2/3 pathway activity and redirected TGF-β signaling to the Acvrl1/Smad1 
axis. However, this cell type is often only used as a cell model for fibroblasts. In order 
to translate these observations into primary cells, fibroblasts were isolated from mouse 
lungs and subjected to the same stimulation protocol used for NIH/3T3 cells            
(Fig. 4.10A,B). As expected TGF-β1 stimulation increased p(CAGA)9 element activity 
(Fig. 4.10A). This was visible by comparing the first and third bar. Comparing the fourth 
with the third bar dex significantly inhibited TGF-β1-stimulated p(CAGA)9 element 
activity (Fig. 4.10A). This observation is in line with the data obtained from the same 
experiment in NIH/3T3 cells. Like in NIH/3T3 cells stimulation with TGF-β1 for 30 min 
resulted in increased Smad2 and Smad3 phosphorylation (Fig. 4.10B). This effect was 
visible when comparing lane three and lane one. As seen in 3T3 cells dex significantly 
inhibited TGF-β1-induced Smad3 phosphorylation whereas TGF-β1-induced Smad1 
phosphorylation was potentiated. This effect was visible when comparing lane four with 
lane three. Smad2 phosphorylation in contrast to 3T3 cells remained unaffected       
(Fig. 4.10B).     
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Fig. 4.11 Dexamethasone modulates Tgfbr1/Smad2/3 and Acvrl1/Smad1 signaling in other pulmonary cell 
types. Primary human pulmonary artery endothelial cells (HPAEC) (A), H441 human Clara cell-like airway epithelial 
cells (B), and primary human pulmonary artery smooth muscle cells (HPASMC) (C) were stimulated with 
dexamethasone [dex] at a concentration of 20 nM for 18 h. Then one group of cells was stimulated with TGF-β1 only 
at a concentration of 2 ng/ml for 30 min. Dexamethasone-treated cells were either then again treated with 
dexamethasone or dexamethasone in combination with TGF-β1 at a concentration of 2 ng/ml for a duration of        
30 min. Media was then removed, cells were washed in ice cold 1× PBS, and finally incubated in lysis buffer. 
Proteins were then isolated in order to assess SMAD1, SMAD2, and SMAD3 phosphorylation by immunoblot 
analysis. 
4.7 Effects of dexamethasone on other constituent cell types of the lung 
Next, the effect of dex and TGF-β1 on Tgfbr1/Smad2/3 and Avcrl1/Smad1 
signaling was analyzed in primary human pulmonary artery endothelial cells (HPAEC), 
primary human pulmonary artery smooth muscle cells (HPASMC), and H441 human 
Clara-like airway epithelial cells (Fig. 4.11). Dexamethasone treatment alone induced 
SMAD1 phosphorylation in HPASMC and H441 cells. This was evident when 
comparing the first and second lane in Fig. 4.11B,C. In HPAEC this was not the case, 
however, when comparing lane four and lane three in Fig. 4.11A, in the presence of 
TGF-β1, SMAD1 phosphorylation was potentiated by dex. The ability of dex to activate 
SMAD1 was demonstrated in all cell types. This observation is interesting as 
corticosteroids, therefore, may be able to activate the Acvrl1/Smad1 pathway in many 
pulmonary cell types. In all cell types TGF-β1 stimulation resulted in SMAD2 and 
SMAD3 phosphorylation (Fig. 4.11A,B,C) which was evident when analyzing lane one 
and lane three. Similar to the observations made in fibroblasts dex strongly inhibited 
TGF-β1-induced SMAD3 activation in HPAEC and HPASMC (Fig. 4.11A,C). 
Interestingly, SMAD2 activation in these cell types behaved in an opposite way       
(Fig. 4.11A,C). When comparing lane four with lane three in Fig. 4.11B,                  
TGF-β1-induced SMAD2 and SMAD3 activation remained resistant to dex treatment in 
H441 cells.  
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Fig. 4.12 Dexamethasone potentiates transforming growth factor-β1-driven fibroblast-to-myofibroblast 
differentiation. A, Primary human adult fibroblasts were treated with dexamethasone [dex; 20 nM], TGF-β1                    
[2 ng/ml], and TGF-β1 [2 ng/ml] for 12 h, after 18 h pre-treatment with dexamethasone. Smooth muscle myosin 
(MYH11) and α-smooth muscle actin (ACTA2) served as markers of myofibroblast differentiation and were assessed 
by immunoblot. In order to quantify protein levels of MYH11 (B) and ACTA2 (C) densitometric analysis was 
performed. Results are presented as mean ± S.D. Experiments were repeated three times. One-way ANOVA and 
Bonferroni post-hoc analyses were used to analyze whether differences between groups were significant.               
P-values <0.05 were considered significant.   
   
4.8 Dexamethasone functionally impacts TGF-β-regulated physiological 
processes 
Fibroblast-to-myofibroblast differentiation plays a crucial pathogenic role in 
inflammatory and fibrotic pulmonary diseases and is characterized by accumulation of 
MYH11 and ACTA2 which has been demonstrated to be an Acvrl1/Smad1-mediated 
process [144, 146-150]. Therefore, the next experiment was aimed at studying the 
effects of dex and TGF-β1 on this process in primary human adult fibroblasts           
(Fig. 4.12). Neither dex, when comparing lane one with lane two in Fig. 4.12A, nor 
TGF-β1, when comparing lane three with lane one in Fig. 4.12A, alone affected MYH11 
protein levels. However, in combination MYH11 protein levels increased indicating a 
potentiating effect on myofibroblast differentiation. This was evident when comparing 
lane three with lane four in Fig. 4.12A. In contrast, when comparing lane one with lane 
two in Fig. 4.12A dex and TGF-β1 stimulation alone increased ACTA2 protein levels in 
human fibroblasts. In combination, this effect was even more pronounced. This effect 
was evident by comparing lane four with lane three and two in Fig. 4.12A. Immunoblot 
data were quantified by densitometric analysis and are presented in Fig. 4.12B and C. 
Overall, these results indicate that myofibroblast differentiation is strongly induced in 
human fibroblasts when stimulated with dex and TGF-β1. This observation is in line 
with previous results demonstrating increased pathway activity of the Acvrl1/Smad1 
axis in fibroblasts stimulated with dex and TGF-β1. This fact may be relevant in respect 
to patients suffering from inflammatory or fibrotic pulmonary diseases and receiving 
glucocorticoid treatment. 
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Fig. 4.13 Dexamethasone drives tgfbr3, acvrl1, and smad1 mRNA expression in whole mouse lung 
homogenates. Dexamethasone [dex] at a concentration of 10 mg/kg body weight was injected intraperitoneally into 
six adult female C57BL/6J mice. Six control adult female C57BL/6J mice received an intraperitoneal injection of 
vehicle. This consisted of 200 µl of 1× PBS. Isoflurane was used to sacrifice all mice after 24 h. After opening the 
abdominal and chest cavities, the lungs, the heart, the kidneys, and the liver were explanted. Proteins and mRNA 
were then isolated according to protocol. Real-time PCR was used to assess relative mRNA levels of smad1, tgfbr3, 
and acvrl1. An unpaired Student’s t-test was used to analyze whether differences between groups were significant. 
P-values <0.05 were considered significant. Fold-induction demonstrates expression changes of target genes 
between dex-treated and control animals. 
   
4.9 Glucocorticoids modulate TGF-β signaling in vivo 
 
4.9.1 Glucocorticoids modulate relative tgfbr3, acvrl1, and smad1 mRNA 
expression levels in whole mouse lung homogenates 
In vitro experiments throughout the whole study demonstrated that 
glucocorticoids were able to redirect TGF-β signaling from the Tgfbr1/Smad2/3 to the 
Acvrl1/Smad1 signaling axis. This effect in fibroblasts resulted in increased 
myofibroblast differentiation which may be of pathophysiological relevance in patients 
suffering from the mentioned pulmonary diseases and receiving glucocorticoid 
treatment. In order to assess the impact of glucocorticoids on in vivo pulmonary 
Tgfbr1/Smad2/3 and Acvrl1/Smad1 signaling, dex (10 mg/kg body weight) was 
intraperitoneally applied to six live adult female C57BL/6J mice (Fig. 4.13).  
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Another six control mice were intraperitoneally-injected with 200 µl vehicle 
consisting of 1× PBS. All mice were sacrificed after 24 h. The lungs, the heart, the 
kidneys, and the liver were explanted for analysis. Relative tgfbr3, acvrl1, and smad1 
mRNA expression levels were increased in whole lung homogenates from dex-treated 
mice (Fig. 4.13A). The induction of these three target genes was only evident in the 
lung. There is no known explanation for this phenomenon. Relative expression of all 
target genes in the kidneys (Fig. 4.13B) remained unchanged. Down-regulation of 
acvrl1 was detected in the liver (Fig. 4.12D). Relative smad1 mRNA levels were 
decreased in the heart (Fig. 4.13C) and the liver (Fig. 4.13D). Overall, these in vivo 
observations demonstrate that intraperitoneal application of dex to live mice results in 
similar in vitro effects of dex on NIH/3T3 cells.  
 
4.9.2 Dexamethasone impacts Acvrl1/Smad1 signaling in whole mouse lung 
homogenates 
Dexamethasone increased relative tgfbr3, acvrl1, and smad1 mRNA expression 
levels in mouse lung homogenates (Fig. 4.13A). In order to assess whether dex 
treatment also affected protein levels immunoblot analyses were performed on proteins 
isolated from whole mouse lung homogenates (Fig. 4.14). Dexamethasone increased 
Tgfbr3 (Fig. 4.14D) and Smad1 (Fig. 4.14C) protein expression in whole mouse lung 
homogenates. This was evident when comparing the first five with the last five bands in 
Fig. 4.14A. Furthermore, when comparing the first five with the last five lanes in        
Fig. 4.14A, total Smad1 levels were also increased in dex-treated animals. Therefore, 
Smad1 phosphorylation was also stronger in dex-treated mice. This was also visible 
when comparing the first five with the last five lanes in the same figure. This indicates 
that increased Smad1 activation is probably the consequence of increased total Smad1 
levels in mouse lungs. Finally, when comparing the last five with the first five lanes in 
Fig. 4.14A, neither phospho-Smad2 nor total Smad2 protein levels were altered in   
dex-treated mice. All immunoblots are quantified in Fig. 4.14B. Unfortunately,  
phospho-Smad3 and total Smad3 protein levels were not reliably detectable. Overall, 
dex injection to live mice increased mRNA and protein expression of Tgfbr3 as well as 
increased acvrl1 mRNA expression. Additionally, dex activated the Acvrl1/Smad1 
pathway in vivo in mouse lungs. This is in line with the observations made in all 
pulmonary cell types. This demonstrates that glucocorticoid and TGF-β signaling 
crosstalk occurs in vivo in mice lungs. Whether this is also the case in human lungs will 
have to be assessed in future studies. 
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Fig. 4.14 Dexamethasone drives total Smad1 and Tgfbr3 protein expression in whole mouse lung 
homogenates. Dexamethasone [dex] at a concentration of 10 mg/kg body weight was injected intraperitoneally into 
six adult female C57BL/6J mice. Six control adult female C57BL/6J mice received an intraperitoneal injection of 
vehicle. This consisted of 200 µl of 1× PBS. Isoflurane was used to sacrifice all mice after 24 h. After opening the 
abdominal and chest cavities, the lungs, the heart, the kidneys, and the liver were explanted. Proteins and mRNA 
were then isolated according to protocol. Immunoblot analysis was used to assess activation of Smad1 and Smad2, 
as well as total Smad1, Smad2, and Tgfbr3 protein expression (A). Densitometry was applied to quantify immunblot 
bands in B, C, and D. Data are presented as mean ± S.D. Each group consisted of five animals. An unpaired 
Student’s t-test was used to analyze whether differences between groups were significant. P-values <0.05 were 
considered significant. 
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5. Discussion 
 Corticosteroids provide outstanding management of asthma. However, this drug 
type has not performed well in patients suffering from ARDS, COPD, IPF, impaired 
lung development, and BPD in pre-term infants. The reasons why glucocorticoids fail to 
help patients suffering from these diseases are not clear. Transforming growth factor-β 
signaling is critically deregulated in all five of these diseases. Therefore, it was 
interesting to explore possible glucocorticoid/TGF-β signaling crosstalk as this might 
give new insights into why glucocorticoids do not help patients who suffer from these 
pulmonary diseases. 
This study revealed that glucocorticoids impacted TGF-β signaling in lung 
fibroblasts. These observations were also made in other pulmonary cell types which 
were included in this study. Finally, glucocorticoid/TGF-β crosstalk was also 
demonstrated in lungs of living mice. Since TGF-β signaling is a disease underlying 
mechanism in inflammatory and fibrotic pulmonary diseases these findings are very 
important. Despite strong anti-inflammatory effects of glucocorticoids, application of 
these drugs to COPD, ARDS, BPD, and IPF patients fails to improve disease outcome. 
The fibroblast cell has been demonstrated to play an important role during normal lung 
development and physiological tissue repair. In inflammatory and fibrotic pulmonary 
diseases, however, this cell type is a key disease-mediating factor. Exploring possible 
glucocorticoid/TGF-β crosstalk in the lung may reveal why corticosteroid treatment fails 
in these lung pathologies. 
 
5.1 Glucocorticoids redirect TGF-β signaling – new mechanistic insights 
 First experiments in this study revealed that glucocorticoids, most notably dex, 
were able to counter proximal Tgfbr1/Smad2/3 signaling by inhibiting phosphorylation 
of the intracellular messengers Smad2 and Smad3 in lung fibroblasts. As a 
consequence, TGF-β-induced Tgfbr1/Smad2/Smad3 downstream pathway activity was 
strongly reduced in the presence of glucocorticoids. Screening of TGF-β receptors and 
co-receptors revealed an upregulation of tgfbr3 on gene and protein levels as a 
consequence of dex treatment. Therefore, it was hypothesized that this accessory 
receptor was somehow involved in mediating dex-induced inhibition of Smad2 and 
Smad3 phosphorylation. Knock-down experiments of tgfbr3 demonstrated that the 
ability of dex to inhibit proximal and distal TGF-β-induced Tgrbr1 pathway activation 
was lost in fibroblasts lacking Tgfbr3. Analysis in this context also revealed that loss of 
Tgfbr3 resulted in a stronger TGF-β-induced Tgfbr1 activation in fibroblasts indicating 
that this co-receptor acts inhibitory on Tgfbr1/Smad2/3 signaling. This was 
demonstrated by increased Smad2 and Smad3 phosphorylation as well as increased 
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TGF-β-responsive p(CAGA)9-driven luciferase production. Interestingly, Smad1 
activation, which lies in the alternative Acvrl1 signaling pathway, behaved completely 
oppositely in fibroblasts lacking Tgfbr3. Dexamethasone treatment not only increased 
Tgfbr3 protein levels but also resulted in increased Smad1 phosphorylation. 
Furthermore, TGF-β1 treatment also drove Smad1 phosphorylation and this effect was 
potentiated in the presence of dex. In the absence of Tgfbr3 activation of Smad1 was 
greatly decreased. Therefore, it can be stated that dex requires Tgfbr3 to redirect  
TGF-β signaling from the Tgfbr1/Smad2/3 pathway to the Acvrl1/Smad1 signaling axis.  
 In order to prove that Tgfbr3 was able to activate Smad1 in the absence of dex, 
the TGFBR3 was overexpressed in NIH/3T3 cells. Cells which were transefected with 
TGFBR3-expressing constructs demonstrated significantly increased Smad1 
phosphorylation and this phenomenon was even more pronounced in the presence of 
TGF-β1. One further experiment also revealed increased Acvrl1/Smad1 downstream 
activation which was detected by dual luciferase assay employing the                 
Smad1-responsive pBRE-luc construct. Overexpression of TGFBR3 in this cell type 
resulted in the same increase of Tgfbr3 protein expression observed in dex-treated 
cells proving that this increase was sufficient to activate the Acvrl1/Smad1 pathway. 
 As mentioned earlier on, dex was also able to increase Smad1 phosphorylation 
whereas this effect can be interpreted as a Tgfbr3-mediated effect. This suggested that 
Smad1 might also be functionally involved in countering Tgfbr1/Smad2/3 signaling. 
Therefore, the next experiments were aimed at assessing Tgfbr1 pathway activation in 
the absence of Smad1 which was achieved in a knock-down experiment employing 
siRNA directed against smad1. Interestingly, similar observations were made as in the 
tgfbr3 knock-down experiments. Transforming growth factor-β1-induced activation of 
the Tgfbr1/Smad2/3 was greatly potentiated in the absence of Smad1 whereas dex lost 
the ability to inhibit Smad2/3 activation as well as downstream activation of            
TGF-β1-driven p(CAGA)9-driven luciferase production in cells lacking smad1.  
 Taken together, glucocorticoids seem to inhibit Tgfbr1/Smad2/3 signaling by 
two related mechanisms. Firstly, dex-induced upregulation of Tgfbr3 results in 
increased Acvrl1/Smad1 activation which secondly, results in decreased activation of 
the Tgfbr1/Smad2/3 pathway by antagonistic effects of phospho-Smad1 on Smad2 and 
Smad3 activation.  
 As NIH/3T3 mouse fibroblast-like cells serve as cell models for fibroblasts, the 
next experiments primary mouse lung fibroblasts were subjected to the same dex and   
TGF-β1 treatment as NIH/3T3 cells. Overall, similar observations were made whereas 
dex potently inhibited TGF-β1-driven Smad3 and p(CAGA)9-driven luciferase 
production. Smad2 activation by TGF-β1 remained unaffected by dex whereas dex 
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potentiated TGF-β1-induced Smad1 activation indicating increased Acvrl1/Smad1 
pathway activity.    
On the basis of this present study it can only be speculated in what way 
betaglycan acts as a “switch” between these major TGF-β signaling axes on a 
functional molecular level in lung fibroblasts. One possible explanation might be that 
Tgfbr3 could facilitate complex formation between Tgfbr2 and Acvrl1, therefore, 
facilitating activation of the Acvrl1/Smad1/5/8 signaling pathway. In the past, 
betaglycan has been demonstrated to interact with the Tgfbr1 and Tgfbr2 in several cell 
types [5]. Depending on cell type and context-dependent mechanisms betaglycan can 
either inhibit or promote signaling properties of certain TGF-β superfamily members [5]. 
Whether this actually is the case on a functional molecular level will have to be the aim 
of future studies investigating the ability of betaglycan to modulate TGF-β signaling in 
lung fibroblasts. 
 
5.2 Glucocorticoids drive fibroblast-to-myofibroblast differentiation 
 The first part of this study focused on exploring mechanistic insights into 
glucocorticoid/TGF-β signaling crosstalk. In the second part experiments were aimed at 
identifying a functional consequence of these observations. Fibroblast-to-myofibroblast 
differentiation is critical for normal physiological wound repair [143]. However, 
dysregulation of this physiological wound repair process has been demonstrated to 
play a pathological role in IPF, BPD, and ARDS [143]. In the past, TGF-β has been 
demonstrated to be a strong activator of this phenomenon [144, 145]. 
Data demonstrated that dex and TGF-β1 synergistically drove ACTA2 and 
MYH11 protein expression in primary human lung fibroblasts. These findings are 
interesting since ACTA2 and MYH11 are both strongly expressed during         
fibroblast-to-myofibroblast differentiation. The expression of ACTA2 has been 
demonstrated to be regulated by the Acvrl1/Smad1 signaling axis [147-150]. 
Dysregulation of Smad1 signaling was demonstrated in a hepatic fibrosis model in rats 
as well as systemic sclerosis in humans, indicating that this signaling pathway may 
play a role in the development and progression of these partly fibrotic               
diseases [103, 104]. Furthermore, Smad1 signaling is activated during experimental 
allergic airway inflammation and suspected of driving pathology [172]. 
Taken together, these recent experimental findings and data from this study 
demonstrating synergism of glucocorticoid and TGF-β signaling in respect to activation 
of the Acvrl1/Smad1 axis and fibroblast-to-myofibroblast differentiation, this might 
provide a possible explanation as to why glucocorticoids have failed to counter 
progression of IPF, BPD, and ARDS. Furthermore, it should be taken into account, that 
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administration of glucocorticoids to critically ill patients suffering from these pulmonary 
diseases may even worsen disease progression due to signaling synergism in respect 
to Acvrl1/Smad1 signaling and activation of fibroblast-to-myofibroblast differentiation. 
 
5.3 Pulmonary effects of dexamethasone in mice  
The last part of this study was aimed at exploring whether intraperitoneal 
application of dex to live mice would lead to similar alterations of pulmonary in vivo 
TGF-β signaling as seen in cell models. Dexamethasone-treated mice revealed 
increased mRNA and protein expression of Tgfbr3 and Smad1 as well as mRNA 
expression of acvrl1 in whole lung homogenates. As a consequence of increased total 
Smad1 levels phosphorylation of Smad1 was significantly increased. Unfortunately, it 
was not possible to reliably detect Smad3 or phospho-Smad3 protein levels in whole 
lung homogenates. Furthermore, Smad2 and phospho-Smad2 protein levels remained 
unaffected, which is consistent with the data obtained from primary lung fibroblasts. 
Interestingly, the observed effects were lung-specific. No changes in mRNA expression 
levels were observed in the kidneys whereas smad1 was decreased in the heart. 
Furthermore, RT PCR analysis in whole liver homogenates revealed decreased 
expression levels of smad1 and acvrl1. The reason why dex only positively impacts 
expression levels of target genes and proteins in the lung are not known. 
Taken together, our observations suggest that glucocorticoids are able to 
potently activate pulmonary in vivo TGF-β/Acvrl1/Smad1 signaling. This is in line with 
our findings in lung fibroblasts. This underlies the idea that application of 
glucocorticoids to patients suffering from certain pulmonary diseases in which 
fibroblast-to-myofibroblast differentiation plays a central role could possibly even 
accelerate disease progression, as myofibroblast differentiation is regulated by the 
Acvrl1/Smad1 signaling pathway. 
 
5.4 Glucocorticoid use in the context of lung development and BPD 
 Antenatal administration of glucocorticoids to pregnant mothers in danger of 
preterm birth have been demonstrated to be beneficial for preterm babies, as they are 
able to drive pulmonary surfactant production, which prevents alveoli from collapsing          
[153, 158]. This ultimately improves the respiratory outcome of preterm newborns. 
However, preterm newborns are at a high risk of developing BPD characterized by 
pulmonary airway and vessel simplification, which ultimately leads to an arrest of lung 
development [94, 121]. The number of alveoli decreases during corticosteroid 
treatment whereas lung maturation is stimulated [153-155].                         
Transforming growth factor-β signaling controls early normal and postnatal lung 
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development. Deregulation of TGF-β signaling plays a central role in the development 
and progression of BPD and CLD. Therefore, it is important to review potential 
glucocorticoid/TGF-β signaling crosstalk in this context [19, 105, 122]. Current 
recommendations state that glucocorticoid therapy is not safe in infants suffering from 
BPD, due to the possibility numerous short- and long-term adverse outcomes, including 
neurodevelopmental impairment [17]. 
 As experiments have demonstrated, conditional overexpression of TGF-β1 in 
fetal monkey lungs between postnatal days 7 and 14 resulted in a BPD-like picture 
[108]. As TGF-β1 mainly signals via the Tgfbr1/Smad2/3 axis, it may be that activation 
of this pathway during this period of lung maturation causes inhibition of alveolarization. 
This study demonstrates that dex inhibits TGF-β1-driven Smad3 phosphorylation in 
lung fibroblasts, human pulmonary artery endothelial cells, and human pulmonary 
artery smooth muscle cells. This possibly suggests that application of glucocorticoids 
during this period could prove beneficial for babies suffering from BPD as it might 
decrease pathological Smad2/3 signaling. 
 However, it must also be taken into account that inhibition of Smad2/3 signaling 
in Smad3-deficient mice between post natal days 14 and 28 caused airspace 
enlargement. This demonstrated that the Smad2/3 signaling had a positive effect on 
alveolarization during this period of lung maturation [21, 105, 109]. This study 
demonstrates that glucocorticoids inhibit Smad3 phosphorylation and thus activation of 
Tgfbr1/Smad2/3 signaling in several constituent cell types of the lung. This might 
explain why antenatal administration of betamethasone to preterm Rhesus monkeys 
resulted in a decreased number of alveoli compared to controls [153, 154]. Therefore, 
impairment of alveolarization is a possibility that should be taken into account when 
treating preterm babies with glucocorticoids. 
 Overall, normal lung development very much depends on TGF-β signaling 
being “just right” between certain time points [110]. Modulation of Tgfbr1/Smad2/3 
signaling should always be considered when preterm neonates are being treated with 
glucocorticoids to increase pulmonary surfactant synthesis in order to prevent alveoli 
from collapsing. However, as experimental studies suggest, the timing of glucocorticoid 
administration may be critical. 
 Bronchopulmonary dysplasia pathogenesis is highly complex. However, 
ventilator-induced lung injury which may also result in local pulmonary hyperoxia 
represents a major risk factor for developing CLD. Unfortunately, intubation of preterm 
newborns may be necessary in order to provide sufficient arterial oxygenation. 
Experiments have revealed that the above-mentioned condition leads to increased 
TGF-β signaling as well as increased myofibroblast differentiation, which is associated 
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with arrested alveolar development [123, 124]. This study demonstrates that dex and 
TGF-β1 synergistically drive myofibroblast differentiation in vitro via the Acvrl1/Smad1 
signaling pathway, which is also activated in adult mice lungs in vivo. This poses the 
question whether administration of glucocorticoids may activate this pathological 
feature of BPD in preterm neonates and ultimately worsen pulmonary outcome. 
 
5.5 Glucocorticoid use in the context of lung disease 
 Idiopathic pulmonary fibrosis is a devastating disease and characterized by 
progressive worsening of dyspnea and lung function and is associated with a poor 
prognosis [13]. Although inflammation seems to play a central role in disease 
development, it does not seem to feature prominently in the pathogenesis of disease 
progression as patients do not benefit from anti-inflammatory therapy                        
[13, 14, 18, 20, 126]. Interestingly, Smad3-deficient mouse lungs demonstrated only 
little evidence of fibrosis and no upregulation of fibrogenesis-associated genes, 
suggesting a key role for Smad3 as an intracellular mediator of TGF-β signaling in the 
pathogenesis of progression in IPF [18, 21]. This observation raises the question why 
glucocorticoids do not negatively impact disease progression, as data from this study 
demonstrates a negative impact of dex on Smad3 phosphorylation and 
Tgfbr1/Smad2/3 downstream activation in lung fibroblasts. 
 A further study revealed that upregulation of CCN2, which represents a strong 
pro-fibrotic component, was mediated by Acvrl1/Smad1 signaling in a model of 
scleroderma fibrosis [173]. This is interesting, since CCN2 is also regulated by the 
Tgfbr1/Smad2/3 axis [77]. Fibroblasts from systemic sclerosis patients demonstrated 
increased Smad1 phosphorylation levels, which strongly correlated with CTGF levels 
and directly increased CCN2 promoter activity [103]. This implicates that classical 
Tgfbr1/Smad2/3 signaling may not be the only major TGF-β pathway dysregulated in 
pulmonary fibrosis. As this study suggests dex and TGF-β1 potently and synergistically 
activate Acvrl1/Smad1 signaling, which could potentially worsen disease progression 
and might be an explanation as to why glucocorticoids do not work in patients suffering 
from this disease. 
 What is also known so far is that glucocorticoids are not able to counter          
IL-13-mediated differentiation of fibroblasts into myofibroblasts, which is also 
dysregulated in pulmonary fibrosis [166, 167]. This is in line with this study’s 
observations, however, from the data it can be concluded that glucocorticoids alone 
and in combination with TGF-β1 synergistically drive myofibroblast differentiation in 
lung fibroblasts which is a Smad1-regulated process. Therefore, it can be concluded 
that glucocorticoids redirect TGF-β signaling towards the (i) potentially pro-fibrotic 
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Acvrl1/Smad1 pathway and (ii) towards increased fibroblast-to-myofibroblast 
differentiation. 
 Further studies employing corticosteroids in pulmonary fibrosis animal studies 
should perhaps specifically target the Acvrl1/Smad1 pathway with inhibitors, and at the 
same time employ glucocorticoids to inhibit classical Tgfbr1/Smad2/3 signaling. 
 
Acute respiratory distress syndrome results in bilateral diffuse pulmonary 
inflammation, which leads to increased pulmonary vascular permeability and ultimately 
to a loss of arterial blood oxygenation [128]. Dysregulation of TGF-β signaling has 
been associated with epithelial destruction and formation of alveolar edema during the 
early phase of ARDS, as well as with progressive pulmonary fibrosis, which can occur 
in the late phase of this disease [22, 129]. 
Glucocorticoids should blunt diffuse pulmonary inflammation and decrease 
vascular permeability but have actually failed to demonstrate benefits for patients 
suffering from this devastating syndrome. It was demonstrated that fibroblast 
proliferation and increased collagen turnover occur in the early phase of ARDS, which 
have both been associated with increased mortality [130-132]. It is known that 
glucocorticoids, when employed in high concentrations, inhibit fibroblast proliferation 
and collagen synthesis [8]. One study employing the dual luciferase ratio assay 
demonstrated that plasmids containing the procollagen I promoter transfected into 
human fibroblasts were induced by stimulation with BALF from ARDS patients, 
whereas specific TGF-β1 antibodies attenuated this effect [130]. Unfortunately, this 
study did not assess proximal TGF-β signaling, as this would have given insights into 
whether this effect is mediated by Tgfbr1/Smad2/3 or the Acvrl1/Smad1/5/8 axis or 
even both. Indeed, as mentioned earlier it can be assumed that certain genes like 
CCN2 can be regulated by both pathways [77, 173]. Therefore, also concluding from 
the data presented in the present study dex strongly reduces TGF-β1-driven Smad3 
activation while Acvrl1/Smad1 signaling in lung fibroblasts is increased, which may be 
bad. 
Similar as observed in IPF and BPD, it can be assumed that dysregulation of      
fibroblast-to-myofibroblast differentiation plays a major role in the pathogenesis of 
ARDS [143]. In this context, it is again possible that, in combination with endogenous 
TGF-β signaling, glucocorticoids could potentially worsen this phenomenon in patients 
suffering from this disease. Therefore, future studies of corticosteroid effects in ARDS 
animal models should assess activation of pulmonary Acvrl1/Smad1 signaling and  
downstream targets of this pathway. 
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Asthma is a chronic disease characterized by inflammation and remodeling of 
the airways, with airway hyper-responsiveness and reduced lung function [96]. 
Transforming growth factor-β1 plays a central role in airway remodeling, which includes 
microvascular changes, airway smooth muscle remodeling and subepithelial fibrosis: 
key histopathological features of asthmatic patients [96, 97]. Together with β2-agonists 
inhaled corticosteroid treatment has been very effective in children and adults suffering 
from asthma [11]. They reduce airway hyperresponsiveness, inhibit inflammatory cell 
migration as well as activation, block late-phase reaction to allergens, and reduce the 
risk of exacerbation [11]. However, in children it is reported that they do not alter 
progression or underlying severity of the disease [11]. 
 One experimental study focussing on airway inflammation found that Smad1 
phosphorylation was greatly increased in bronchial epithelial cells in experimental 
allergic airway inflammation [172]. It is suspected that this could possibly drive 
pathology. This study demonstrates that dex drives phosphorylation of SMAD1 in 
human H441 cells which serve as a cell model for bronchial epithelial cells. 
Interestingly, dex did not counter TGF-β1-driven SMAD2 and SMAD3 phosphorylation 
in this cell type. This demonstrates two important facts: namely that (i) dex may 
possibly drive SMAD1 signaling, which is a potential disease-underlying pathway in 
asthmatic patients and (ii) dex does not counter classical TGFBR1/SMAD2/3 signaling 
in this cell type, which is also dysregulated in asthma. 
 
Chronic obstructive pulmonary disease is characterized by chronic airway 
inflammation accompanied by irreversible expiratory airflow limitation, which is caused 
by SAD and emphysema [96]. Chronic inflammation and dysregulation of TGF-β 
signaling are central mediators in disease pathology [96]. Interestingly, TGF-β signaling 
seems to behave in contradictory ways in SAD and emphysema. While TGF-β 
signaling seems to be increased in small airway epithelium, decreased TGF-β signaling 
seems to contribute to airway enlargement and emphysema [119, 134, 138, 142]. 
Inhaled corticosteroids have been demonstrated to reduce symptoms of dyspnea and 
the number of exacerbations, but have failed to reduce the frequency of 
hospitalizations [12, 168, 169]. Overall, corticosteroid treatment cannot counter 
progression of this disease. The reason for this is not apparent. If the data from this 
study are interpreted in the context of COPD, two important facts come to mind. First of 
all, as mentioned in the context of asthma, human epithelial cells are resistant to     
dex-mediated inhibition of TGFBR1/SMAD2/3 signaling. This might also be the case in 
COPD patients. Secondly, dex, the inhaled corticosteroids flu and bud, decrease 
Tgfbr1/Smad2/3 in lung fibroblasts, suggesting that this may potentially have an 
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adverse effect on the development of emphysema, as decreased Smad3 signaling 
seems to contribute to the development of airspace enlargement. 
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10. Appendix 
 
Table 10.1 List of primary mouse/human antibodies 
 
Primary Host Dilution Company Catalog 
number 
anti-phospho 
Smad1/5/8 
rabbit 1:800 Cell Signaling 
Technology  
#9511 
anti-phospho 
Smad2 
rabbit 1:1000 Cell Signaling 
Technology  
#3101 
anti-phospho 
Smad3 
rabbit 1:1000 Cell Signaling 
Technology  
#9520 
anti-total 
Smad1 
rabbit 1:1000 Cell Signaling 
Technology  
#9743 
anti-total 
Smad2 
mouse 1:1000 Cell Signaling 
Technology  
#3103 
anti-total 
Smad2/3 
rabbit 1:1000 Cell Signaling 
Technology  
#3102 
anti-Tgfbr3 rabbit 1:1000 Cell Signaling 
Technology  
#2519 
anti-β-actin rabbit 1:1000 Cell Signaling 
Technology  
#4967 
anti-smooth 
muscle 
myosin 
(MYH11) 
rabbit 1:1000 Abcam ab53219 
anti-α-smooth 
muscle actin 
(ACTA2) 
rabbit 1:1000 Sigma A-2547 
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Table 10.2 List of secondary antibodies 
 
Secondary Host Dilution Company Catalog 
number 
Peroxidase-
conjugated 
anti-rabbit IgG 
goat 1:3000 Thermofisher 
Scientific  
rb:31640 
Peroxidase-
conjugated 
anti-mouse 
IgG  
goat 1:3000 Thermofisher 
Scientific  
ms:31450 
 
 
Table 10.3 List of mouse primers for quantitative real-time PCR 
 
Gene 
name 
Forward primer [5′-3′] Reverse Primer [5′-3′] Amplification size  
[bp] 
Number 
of cycles 
Annealing 
temperature 
[°C] 
tgfbr3 ATGGCAGTGACATCCC
ACCACAT 
AGAACGGTGAAGCTCTC
CATCA 
152 45 60.0 
acvrl1 CACCTACATGTGGAGA
TCT 
CGATATCCAGGTAATCGC
TG 
160 45 60.0 
smad1 GCCTCTGGAATGCTGT
GAGTTCCCA 
GAGCCAGAAGGCTGTGC
TGAGCA 
152 45 60.0 
gapdh ATGGTGAAGGTCGGTG
TGAA 
TCATACTGGAACATGTAG
ACC 
143 45 60.0 
 
 
Table 10.4 List of mouse small interfering RNA 
 
Gene name Company Catalog number 
tgfbr3 Santa Cruz Biotechnology, 
Inc., USA 
sc-40225 
smad1 Santa Cruz Biotechnology, 
Inc., USA 
sc-40213 
scrambled siRNA Ambion® Life 
TechnologiesTM, USA 
AM-4611 
 
